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ABSTRACT OF THE DISSERTATION 
 
Role of the Gut Microbiome in Polycystic Ovary Syndrome 
by 
Pedro Jahir Torres 
Doctor of Philosophy in Biology 
University of California San Diego, 2019 
San Diego State University, 2019 
Professor Scott T. Kelley, Chair 
 
 Polycystic ovary syndrome (PCOS) is the most common endocrine disorder in 
reproductive-aged women worldwide. In addition to infertility, many women with PCOS have 
metabolic abnormalities that result in an increased risk of type 2 diabetes and cardiovascular 
disease. Although the etiology of PCOS is poorly understood, accumulating evidence suggests 
that androgen excess is an important contributor to the pathogenesis of PCOS.  The human 
large intestine contains a complex community of microorganisms (the gut microbiome) 
important for human health and disease. Studies have shown that the gut microbiome is 
altered in humans with metabolic disorders such as obesity and type 2 diabetes, and that the 
gut microbiome may be a causal factor in the development of these disorders.  Dysbiosis of 
the gut microbiome has been proposed to factor in the development of PCOS and studies have 
shown that changes in the gut microbiome are associated with PCOS in women 
xv 
and in rodent models. However, it is unknown if the gut microbiome plays a causal role in the 
PCOS phenotype. For this dissertation I used human fecal samples and a letrozole-induced 
PCOS mouse model together with 16S rRNA gene sequencing to further our understanding of 
the effects of androgen excess and the role of the gut microbiome in PCOS. Using human 
fecal samples and patient clinical parameters, the results in chapter 1 suggest that androgen 
excess may play a critical role in altering the gut microbiome in women with PCOS. Since 
there is considerable variation in the human gut microbiome due to differences in diet and 
ethnicity, chapters 2 and 3 used a PCOS mouse model to gain more insight into the 
pathophysiology of PCOS. The results from chapter 2 indicate that dysregulation of the 
metabolism and gut microbiome in PCOS may be influenced by the timing of androgen 
exposure. Lastly, the results from chapter 3 showed that exposure to a healthy gut microbiome 
improved the metabolic and reproductive phenotype in a PCOS mouse model. Overall, these 
results suggest that modulating the composition of the gut microbiome may be a potential 
treatment option for women with PCOS.
 1 
INTRODUCTION 
 
Polycystic Ovary Syndrome (PCOS) 
Polycystic ovary syndrome (PCOS) is the most common endocrine disorder in 
reproductive-aged women with an estimated world-wide prevalence of ~10% [1]. PCOS was 
first described in 1935 by Drs. Irving Stein and Michael Leventhal as a group of patients who 
demonstrated a combination of hirsutism (male-pattern terminal hair growth in women), 
chronic anovulation and polycystic ovaries [2, 3]. Since then, there have been several 
diagnostic criteria proposed for PCOS: 1. The NIH criteria (1990), which requires 
hyperandrogenism and oligo- or amenorrhea; 2. the Androgen Excess Society criteria (2006), 
which requires hyperandrogenism and ovulatory dysfunction (e.g., oligo- or amenorrhea 
and/or polycystic ovaries; and the most widely used PCOS classification 3. the Rotterdam 
Consensus criteria (2003), which requires at least two of the following: androgen excess 
(hyperandrogenemia and/or hirsutism), ovarian dysfunction (oligo- or amenorrhea) and/or 
polycystic ovarian morphology (PCOM) [4]. The most severe clinical manifestation is the 
classical PCOS phenotype in which women present with both hyperandrogenism and oligo-
ovulation irrespective of polycystic ovaries. The next most severe phenotype is ovulatory 
PCOS in which women present with hyperandrogenism and polycystic ovaries. The non-
hyperandrogenic phenotype, which consists of oligo-ovulation and polycystic ovaries, is the 
least severe phenotype [5]. 
PCOS Pathophysiology 
Although the etiology of PCOS is poorly understood, familial clustering indicates that 
there is a genetic component [6-8]. Twin studies comparing the correlation of PCOS diagnosis 
between monozygotic and dizygotic twins have estimated the heritability of PCOS as ~70%, 
but no clear mode of inheritance has been identified [9]. Altered expression of genes involved 
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in signal transduction pathways controlling steroidogenesis, steroid hormone action, 
gonadotropin action and regulation, insulin action and secretion, energy homeostasis and 
chronic inflammation have been described in PCOS [10-12]. While results have been 
promising, there are no genes universally accepted as fundamentally important in PCOS 
pathophysiology. Heritability is commonly assumed to reflect the effects of inherited genomic 
variation; however, it may also reflect the effects from shared disease-predisposing 
environments e.g. daughters of a woman with PCOS would be exposed to the same 
intrauterine environment. Prenatal exposure to androgens in female rodent and primate studies 
have also implicated the intrauterine environment in PCOS pathogenesis [13-15]. Evidence 
suggest that the intrauterine environment in pregnant PCOS women is also hyperandrogenic 
[16]. The clinical manifestations of PCOS often emerge in adolescence or the early 
reproductive years, suggesting that puberty may be a critical time in the development and 
pathology of PCOS [17, 18]. Indeed, PCOS has been hypothesized to originate form abnormal 
pubertal development due to a lack of transition from an androgen-dominated state in early 
puberty to an estrogenic state in late puberty [19, 20]. Altogether, mounting evidence suggest 
that PCOS might be a complex multifactorial disorder that arises from interactions among 
genetic, environmental and intrauterine factors.  
Women with PCOS often suffer from profound, long-term health issues [21]. PCOS is 
the leading cause of anovulatory infertility in women and increases the likelihood of 
miscarriage and pregnancy complications [22, 23]. In addition, a majority of women with 
PCOS have abnormalities that increase their risk of developing metabolic disease [4, 24-28]. 
Obesity is a common finding in women with PCOS and approximately 80% of women with 
PCOS in the United States are obese [29]. Moreover, obesity exacerbates many of the 
reproductive and metabolic abnormalities associated with PCOS [30]. Insulin resistance is 
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another common feature of women with PCOS, which cannot be fully explained by the 
frequent association with obesity because PCOS women are more insulin resistant than 
healthy controls matched for body mass index (BMI) [31, 32]. Insulin resistance occurs in 
75% of non-obese and 95% of obese women with PCOS [33]. In addition to obesity and 
insulin resistance, studies have shown that PCOS is associated with abdominal adiposity, 
hyperinsulinemia, glucose intolerance, and dyslipidemia [34-37]. These associated disorders 
directly increase the risk of metabolic syndrome, type 2 diabetes, gestational diabetes, non-
alcoholic fatty liver disease and cardiovascular disease [25, 38-40]. Studies have shown that 
hyperandrogenism is strongly correlated with development of a metabolic phenotype [41-43]. 
Metabolic dysfunction occurs predominately in women diagnosed with hyperandrogenism 
and ovulatory dysfunction, independent of BMI [7, 44, 45]. Given the limitations of current 
treatments for metabolic symptoms of PCOS, there is a significant need for studies addressing 
the development and pathophysiology of the PCOS metabolic phenotype. 
Gut Microbiome and PCOS 
The human large intestine contains a complex community of microorganism (the gut 
microbiome) important for human health and disease [46, 47]. Gut microbes offer many 
benefits to the host including protection against pathogens as well as education of our immune 
system and integrity of the intestinal barrier [48-50]. The gut microbiome is also involved in 
the production of short-chain fatty acids via fermentation of dietary soluble fibers, production 
of essential vitamins such as folic acid and B12 and modification of bile acids, 
neurotransmitters and hormones [51, 52]. Correlative studies have demonstrated that the gut 
microbiome of individuals with metabolic disorders, such as obesity and diabetes, differs 
significantly from healthy individuals [46, 53-57]. Moreover, studies have reported that 
transplantation of stool from obese donors into germ-free mice results in an obese phenotype, 
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suggesting that the gut microbiome may play a causative role in metabolic dysregulation [56]. 
These transplantation studies were complemented with co-housing studies that took advantage 
of the fact that, since mice are coprophagic, co-housing provides a means for repeated, non-
invasive microbial inoculation. Co-housing germ free mice transplanted with stool from obese 
donors with germ-free mice transplanted with stool from lean donors was shown to protect the 
mice transplanted with obese donor stool from developing obesity [56, 58, 59]. Altogether, 
these studies suggest that modulation of the gut microbiome may be a potential treatment 
option for metabolic disorders. 
 Dysbiosis of the gut microbiome has been proposed to contribute to the development 
of PCOS and studies using 16S rRNA gene amplicon sequencing have shown that changes in 
the gut microbiome are associated with PCOS [46, 60-63]. Women diagnosed with PCOS 
using the Rotterdam criteria were reported to have a significant reduction in the overall gut 
bacterial species richness (alpha diversity), shifts in gut microbial composition (beta diversity) 
and changes in abundance of several bacterial taxa compared to healthy women. 
Letrozole Induced PCOS Mouse Model 
Since hyperandrogenism is associated with PCOS, researchers have created animal 
models to study the role of androgens in the development and pathology of PCOS [64-68]. 
Several mouse models were developed using treatment with exogenous dihydrotestosterone 
but these models did not exhibit the elevated luteinizing hormone (LH) levels associated with 
PCOS [69-73]. A PCOS mouse model was developed in pubertal female mice using treatment 
with the aromatase inhibitor, letrozole, to limit the conversion of testosterone to estrogen 
which results in increased testosterone and decreased estrogen levels. This model is based on 
the findings that genetic variants of the aromatase gene are associated with the development 
of PCOS in women and that a higher androgen/estrogen ratio is found in the ovaries of 
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women with PCOS [74-78]. Letrozole treatment of pubertal female mice results in the 
reproductive hallmarks of PCOS including hyperandrogenism, acyclicity, polycystic ovaries, 
and elevated LH levels [79-81]. This model also exhibits metabolic dysregulation similar to 
the phenotype in women with PCOS including weight gain, abdominal adiposity, increased 
fasting blood glucose and impaired insulin levels, impaired glucose stimulated-insulin 
secretion, insulin resistance and dyslipdemia [79-81]. Letrozole treatment does not alter food 
intake or energy expenditure, even though locomotion was decreased, suggesting that other 
mechanisms contribute to the metabolic dysregulation in this model [81]. Similar to women 
with PCOS, 16S rRNA gene sequencing showed that letrozole treatment was associated with 
a significant decrease in the alpha diversity and a shift in overall gut microbial composition 
(beta diversity) [80]. A recent study examining the effects of non-antibiotic drugs on the gut 
microbiome found that letrozole did not alter the growth of ~40 representatives gut bacteria 
[82], this suggest that differences in the gut microbial composition found in the PCOS mouse 
model are not due to a direct effect of letrozole.  
The results obtained from the studies presented in this thesis have increased our 
understanding of the role of hyperandrogenism in shaping the gut microbiome of women with 
PCOS, how timing of excess androgen exposure may be an important component in the 
development of the PCOS phenotype and how exposure to a healthy gut microbiome can help 
improve the PCOS metabolic and reproductive phenotype. All together, these studies provide 
insight into the pathophysiology of PCOS and suggest that dysbiosis of the gut microbiome 
may play a causal role in PCOS and that modulation of the gut microbiome may be a potential 
treatment option for women with this disorder.  
 
 6 
REFERENCES 
 
1. Fauser, B.C.J.M., et al., Consensus on women's health aspects of polycystic ovary 
syndrome (PCOS): the Amsterdam ESHRE/ASRM-Sponsored 3rd PCOS Consensus 
Workshop Group. Fertility and sterility, 2012. 97(1): p. 28-38.e25. 
 
2. Azziz, R. and E.Y. Adashi, Stein and Leventhal: 80 years on., in Am. J. Obstet. 
Gynecol. 2016. p. 247.e1-247.e11. 
 
3. Stein, I.F. and M.L. Leventhal, Amenorrhea associated with bilateral polycystic 
ovaries, in Am. J. Obstet. Gynecol. 1935. p. 181-191. 
 
4. Fauser, B.C., et al., Consensus on women's health aspects of polycystic ovary 
syndrome (PCOS): the Amsterdam ESHRE/ASRM-Sponsored 3rd PCOS Consensus 
Workshop Group. Fertil Steril, 2012. 97(1): p. 28-38 e25. 
 
5. Escobar-Morreale, H.F., Reproductive endocrinology: Menstrual dysfunction--a proxy 
for insulin resistance in PCOS? Nat Rev Endocrinol, 2014. 10(1): p. 10-1. 
 
6. Barber, T.M. and S. Franks, Genetics of Polycystic Ovary Syndrome. 2012. 40: p. 28-
39. 
 
7. Barber, T.M., et al., Metabolic characteristics of women with polycystic ovaries and 
oligo-amenorrhoea but normal androgen levels: implications for the management of 
polycystic ovary syndrome. Clin Endocrinol (Oxf), 2007. 66(4): p. 513-7. 
 
8. Legro, R.S., et al., Evidence for a genetic basis for hyperandrogenemia in polycystic 
ovary syndrome. Proc Natl Acad Sci U S A, 1998. 95(25): p. 14956-60. 
 
9. Vink, J.M., et al., Heritability of polycystic ovary syndrome in a Dutch twin-family 
study. J Clin Endocrinol Metab, 2006. 91(6): p. 2100-4. 
 
10. Barber, T.M. and S. Franks, Genetics of polycystic ovary syndrome. Front Horm Res, 
2013. 40: p. 28-39. 
 
11. Xita, N., I. Georgiou, and A. Tsatsoulis, The genetic basis of polycystic ovary 
syndrome. Eur. J. Endocrinol., 2002. 147(6): p. 717-25. 
 
12. De Leo, V., et al., Genetic, hormonal and metabolic aspects of PCOS: an update. 
Reprod Biol Endocrinol, 2016. 14(1): p. 38. 
 
13. Abbott, D.H., et al., Androgen excess fetal programming of female reproduction: a 
developmental aetiology for polycystic ovary syndrome? Hum. Reprod. Update, 2005. 
11(4): p. 357-374. 
 
 7 
14. Wu, X.Y., et al., Endocrine traits of polycystic ovary syndrome in prenatally 
androgenized female Sprague-Dawley rats. Endocr J, 2010. 57(3): p. 201-9. 
 
15. Sherman, S.B., et al., Prenatal androgen exposure causes hypertension and gut 
microbiota dysbiosis. Gut Microbes, 2018. 9(5): p. 400-421. 
 
16. Palomba, S., et al., Pervasive developmental disorders in children of hyperandrogenic 
women with polycystic ovary syndrome: a longitudinal case-control study. Clin 
Endocrinol (Oxf), 2012. 77(6): p. 898-904. 
 
17. Abbott, D.H. and F. Bacha, Ontogeny of polycystic ovary syndrome and insulin 
resistance in utero and early childhood. Fertil Steril, 2013. 100(1): p. 2-11. 
 
18. Anderson, A.D., C.M. Solorzano, and C.R. McCartney, Childhood obesity and its 
impact on the development of adolescent PCOS. Semin Reprod Med, 2014. 32(3): p. 
202-13. 
 
19. Ankarberg, C. and E. Norjavaara, Diurnal rhythm of testosterone secretion before and 
throughout puberty in healthy girls: Correlation with 17 beta-estradiol and 
dehydroepiandrosterone sulfate. Journal of Clinical Endocrinology & Metabolism, 
1999. 84(3): p. 975-984. 
 
20. Nader, S., Hyperandrogenism during puberty in the development of polycystic ovary 
syndrome. Fertility and Sterility, 2013. 100(1): p. 39-42. 
 
21. Teede, H., A. Deeks, and L. Moran, Polycystic ovary syndrome: a complex condition 
with psychological, reproductive and metabolic manifestations that impacts on health 
across the lifespan. Bmc Medicine, 2010. 8. 
 
22. Balen, A.H., S.L. Tan, and H.S. Jacobs, Hypersecretion of luteinising hormone: a 
significant cause of infertility and miscarriage. Br J Obstet Gynaecol, 1993. 100(12): 
p. 1082-9. 
 
23. Boomsma, C.M., et al., A meta-analysis of pregnancy outcomes in women with 
polycystic ovary syndrome. Hum Reprod Update, 2006. 12(6): p. 673-83. 
 
24. Azziz, R., et al., The Androgen Excess and PCOS Society criteria for the polycystic 
ovary syndrome: the complete task force report. Fertil Steril, 2009. 91(2): p. 456-88. 
 
25. Carmina, E., A.M. Campagna, and R.A. Lobo, A 20-year follow-up of young women 
with polycystic ovary syndrome. Obstet Gynecol, 2012. 119(2 Pt 1): p. 263-9. 
 
26. Wild, R.A., et al., Assessment of cardiovascular risk and prevention of cardiovascular 
disease in women with the polycystic ovary syndrome: a consensus statement by the 
Androgen Excess and Polycystic Ovary Syndrome (AE-PCOS) Society. J Clin 
Endocrinol Metab, 2010. 95(5): p. 2038-49. 
 
 8 
27. Wild, S., et al., Cardiovascular disease in women with polycystic ovary syndrome at 
long-term follow-up: a retrospective cohort study. Clin Endocrinol (Oxf), 2000. 52(5): 
p. 595-600. 
 
28. Moran, L.J., et al., Impaired glucose tolerance, type 2 diabetes and metabolic 
syndrome in polycystic ovary syndrome: a systematic review and meta-analysis. Hum 
Reprod Update, 2010. 16(4): p. 347-63. 
 
29. Dumesic, D.A., et al., Scientific Statement on the Diagnostic Criteria, Epidemiology, 
Pathophysiology, and Molecular Genetics of Polycystic Ovary Syndrome, in Endocr. 
Rev. 2015, Endocrine Society Washington, DC. p. 487-525. 
 
30. Sam, S., Obesity and Polycystic Ovary Syndrome. Obes Manag, 2007. 3(2): p. 69-73. 
 
31. Dunaif, A., Insulin resistance and the polycystic ovary syndrome: mechanism and 
implications for pathogenesis. Endocr Rev, 1997. 18(6): p. 774-800. 
 
32. Dunaif, A., et al., Evidence for distinctive and intrinsic defects in insulin action in 
polycystic ovary syndrome., in Diabetes. 1992. p. 1257-1266. 
 
33. Stepto, N.K., et al., Women with polycystic ovary syndrome have intrinsic insulin 
resistance on euglycaemic-hyperinsulaemic clamp. Hum Reprod, 2013. 28(3): p. 777-
84. 
 
34. Diamanti-Kandarakis, E., et al., Pathophysiology and types of dyslipidemia in PCOS, 
in Trends in Endocrinology &amp; Metabolism. 2007. p. 280-285. 
 
35. Göbl, C.S., et al., To Assess the Association between Glucose Metabolism and Ectopic 
Lipid Content in Different Clinical Classifications of PCOS., in PLoS ONE. 2016, 
Public Library of Science. p. e0160571. 
 
36. Pasquali, R. and A. Gambineri, Glucose intolerance states in women with the 
polycystic ovary syndrome. Journal of endocrinological investigation, 2013. 36(8): p. 
648-53. 
 
37. Vrbikova, J., et al., Insulin sensitivity in women with polycystic ovary syndrome. The 
Journal of clinical endocrinology and metabolism, 2004. 89(6): p. 2942-5. 
 
38. Barbieri, R.L., et al., Insulin stimulates androgen accumulation in incubations of 
ovarian stroma obtained from women with hyperandrogenism. J Clin Endocrinol 
Metab, 1986. 62(5): p. 904-10. 
 
39. Diamanti-Kandarakis, E. and A. Dunaif, Insulin resistance and the polycystic ovary 
syndrome revisited: an update on mechanisms and implications. Endocr Rev, 2012. 
33(6): p. 981-1030. 
 
 9 
40. Vassilatou, E., Nonalcoholic fatty liver disease and polycystic ovary syndrome., in 
WJG. 2014. p. 8351-8363. 
 
41. Lerchbaum, E., et al., Hyperandrogenemia in polycystic ovary syndrome: exploration 
of the role of free testosterone and androstenedione in metabolic phenotype. PLoS 
One, 2014. 9(10): p. e108263. 
 
42. Alpanes, M., et al., Influence of adrenal hyperandrogenism on the clinical and 
metabolic phenotype of women with polycystic ovary syndrome. Fertil Steril, 2015. 
103(3): p. 795-801 e2. 
 
43. Yang, R., et al., Effects of hyperandrogenism on metabolic abnormalities in patients 
with polycystic ovary syndrome: a meta-analysis, in Reprod. Biol. Endocrinol. 2016, 
Reproductive Biology and Endocrinology. p. 1-10. 
 
44. Moghetti, P., et al., Divergences in Insulin Resistance Between the Different 
Phenotypes of the Polycystic Ovary Syndrome. The Journal of Clinical Endocrinology 
& Metabolism, 2013. 98(4): p. E628-E637. 
 
45. Albu, A., et al., Biochemical hyperandrogenism is associated with metabolic 
syndrome independently of adiposity and insulin resistance in Romanian polycystic 
ovary syndrome patients. Endocrine, 2015. 48(2): p. 696-704. 
 
46. Clemente, J.C., et al., The impact of the gut microbiota on human health: an 
integrative view. Cell, 2012. 148(6): p. 1258-70. 
 
47. Walker, A.W. and T.D. Lawley, Therapeutic modulation of intestinal dysbiosis. 
Pharmacol Res, 2013. 69(1): p. 75-86. 
 
48. Baumler, A.J. and V. Sperandio, Interactions between the microbiota and pathogenic 
bacteria in the gut. Nature, 2016. 535(7610): p. 85-93. 
 
49. Gensollen, T., et al., How colonization by microbiota in early life shapes the immune 
system. Science, 2016. 352(6285): p. 539-44. 
 
50. Natividad, J.M. and E.F. Verdu, Modulation of intestinal barrier by intestinal 
microbiota: pathological and therapeutic implications. Pharmacol Res, 2013. 69(1): p. 
42-51. 
 
51. den Besten, G., et al., The role of short-chain fatty acids in the interplay between diet, 
gut microbiota, and host energy metabolism. Journal of Lipid Research, 2013. 54(9): 
p. 2325-2340. 
 
52. Ridlon, J.M., et al., Bile acids and the gut microbiome. Curr Opin Gastroenterol, 2014. 
30(3): p. 332-8. 
 
 10 
53. Qin, J., et al., A metagenome-wide association study of gut microbiota in type 2 
diabetes. Nature, 2012. 490(7418): p. 55-60. 
 
54. Karlsson, F.H., et al., Gut metagenome in European women with normal, impaired 
and diabetic glucose control. Nature, 2013. 498(7452): p. 99-103. 
 
55. Ley, R.E., et al., Microbial ecology: human gut microbes associated with obesity. 
Nature, 2006. 444(7122): p. 1022-3. 
 
56. Turnbaugh, P.J., et al., A core gut microbiome in obese and lean twins. Nature, 2009. 
457(7228): p. 480-4. 
 
57. Larsen, N., et al., Gut microbiota in human adults with type 2 diabetes differs from 
non-diabetic adults. PLoS One, 2010. 5(2): p. e9085. 
 
58. Turnbaugh, P.J., et al., An obesity-associated gut microbiome with increased capacity 
for energy harvest. Nature, 2006. 444(7122): p. 1027-31. 
 
59. Ridaura, V.K., et al., Gut microbiota from twins discordant for obesity modulate 
metabolism in mice. Science, 2013. 341(6150): p. 1241214. 
 
60. Tremellen, K. and K. Pearce, Dysbiosis of Gut Microbiota (DOGMA)--a novel theory 
for the development of Polycystic Ovarian Syndrome. Med Hypotheses, 2012. 79(1): 
p. 104-12. 
 
61. Lindheim, L., et al., Alterations in Gut Microbiome Composition and Barrier Function 
Are Associated with Reproductive and Metabolic Defects in Women with Polycystic 
Ovary Syndrome (PCOS): A Pilot Study. PLoS One, 2017. 12(1): p. e0168390. 
 
62. Liu, R., et al., Dysbiosis of Gut Microbiota Associated with Clinical Parameters in 
Polycystic Ovary Syndrome. Frontiers in Microbiology, 2017. 8. 
 
63. Guo, Y.J., et al., Association between Polycystic Ovary Syndrome and Gut 
Microbiota. Plos One, 2016. 11(4). 
 
64. Padmanabhan, V. and A. Veiga-Lopez, Animal models of the polycystic ovary 
syndrome phenotype, in Steroids. 2013. p. 734-740. 
 
65. Shi, D. and D.F. Vine, Animal models of polycystic ovary syndrome: a focused review 
of rodent models in relationship to clinical phenotypes and cardiometabolic risk., in 
Fertil. Steril. 2012. p. 185-193. 
 
66. van Houten, E.L.A.F. and J.A. Visser, Mouse models to study polycystic ovary 
syndrome: a possible link between metabolism and ovarian function? Reproductive 
biology, 2014. 14(1): p. 32-43. 
 
 11 
67. Walters, K.A., C.M. Allan, and D.J. Handelsman, Rodent models for human polycystic 
ovary syndrome. Biol Reprod, 2012. 86(5): p. 149, 1-12. 
 
68. Walters, K.A., Androgens in polycystic ovary syndrome: lessons from experimental 
models. Current opinion in endocrinology, diabetes, and obesity, 2016. 23(3): p. 257-
63. 
 
69. Caldwell, A.S.L., et al., Characterization of Reproductive, Metabolic, and Endocrine 
Features of Polycystic Ovary Syndrome in Female Hyperandrogenic Mouse Models. 
Endocrinology, 2014. 155(8): p. 3146-3159. 
 
70. Moore, A.M., M. Prescott, and R.E. Campbell, Estradiol negative and positive 
feedback in a prenatal androgen-induced mouse model of polycystic ovarian 
syndrome. Endocrinology, 2013. 154(2): p. 796-806. 
 
71. Roland, A.V., et al., Prenatal androgen exposure programs metabolic dysfunction in 
female mice. J Endocrinol, 2010. 207(2): p. 213-23. 
 
72. Witham, E.A., et al., Prenatal exposure to low levels of androgen accelerates female 
puberty onset and reproductive senescence in mice. Endocrinology, 2012. 153(9): p. 
4522-32. 
 
73. van Houten, E.L., et al., Reproductive and metabolic phenotype of a mouse model of 
PCOS. Endocrinology, 2012. 153(6): p. 2861-9. 
 
74. Barontini, M., M.C. Garcia-Rudaz, and J.D. Veldhuis, Mechanisms of hypothalamic-
pituitary-gonadal disruption in polycystic ovarian syndrome. Arch Med Res, 2001. 
32(6): p. 544-52. 
 
75. Nelson, V.L., et al., Augmented androgen production is a stable steroidogenic 
phenotype of propagated theca cells from polycystic ovaries. Mol Endocrinol, 1999. 
13(6): p. 946-57. 
 
76. Naessen, T., et al., Steroid profiles in ovarian follicular fluid in women with and 
without polycystic ovary syndrome, analyzed by liquid chromatography-tandem mass 
spectrometry. Fertil Steril, 2010. 94(6): p. 2228-33. 
 
77. Xita, N., et al., CYP19 gene: a genetic modifier of polycystic ovary syndrome 
phenotype. Fertil Steril, 2010. 94(1): p. 250-4. 
 
78. Wang, H., et al., A common polymorphism in the human aromatase gene alters the 
risk for polycystic ovary syndrome and modifies aromatase activity in vitro. Mol Hum 
Reprod, 2011. 17(6): p. 386-91. 
 
79. Kauffman, A.S., et al., A novel letrozole model recapitulates both the reproductive 
and metabolic phenotypes of Polycystic Ovary Syndrome in female mice. Biol Reprod, 
2015. 93(3): p. 69. 
 12 
 
80. Kelley, S.T., et al., The Gut Microbiome Is Altered in a Letrozole-Induced Mouse 
Model of Polycystic Ovary Syndrome. PLoS One, 2016. 11(1): p. e0146509. 
 
81. Skarra, D.V., et al., Hyperandrogenemia Induced by Letrozole Treatment of Pubertal 
Female Mice Results in Hyperinsulinemia Prior to Weight Gain and Insulin 
Resistance. Endocrinology, 2017. 158(9): p. 2988-3003. 
 
82. Maier, L., et al., Extensive impact of non-antibiotic drugs on human gut bacteria. 
Nature, 2018. 555(7698): p. 623-628. 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 13 
CHAPTER 1 
 
Gut Microbial Diversity in Women with Polycystic Ovary Syndrome Correlates with 
Hyperandrogenism  
 
Pedro J. Torres1*, Martyna Siakowska2*, Beata Banaszewska2, Leszek Pawelczyk2, Antoni J. 
Duleba3, Scott T. Kelley1, Varykina G. Thackray3  
*Co-first author  
 
1Department of Biology, San Diego State University, San Diego, CA, USA; 2Department of 
Gynecology, Obstetrics and Gynecological Oncology, Poznan University of Medical 
Sciences, Poznan, Poland; 3Department of Reproductive Medicine, University of California, 
San Diego, La Jolla, CA, USA 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 14 
 
C L I N I C A L R E S E A R C H A R T I C L E
GutMicrobialDiversity inWomenWithPolycysticOvary
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Context:Amajority of womenwith polycystic ovary syndrome (PCOS) havemetabolic abnormalities
that result in an increased risk of developing type 2 diabetes and heart disease. Correlative studies
have shown an association between changes in the gut microbiome and metabolic disorders. Two
recent studies reported a decrease in a diversity of the gut microbiome in women with PCOS
compared with healthy women.
Objective:We investigated whether changes in the gut microbiome correlated with specific clinical
parameters in women with PCOS compared with healthy women. We also investigated whether
there were changes in the gut microbiome in women with polycystic ovarian morphology (PCOM)
who lacked the other diagnostic criteria of PCOS.
Participants: Subjects were recruited at the Poznan University of Medical Sciences. Fecal microbial
diversity profiles of healthy women (n = 48), womenwith PCOM (n = 42), andwomen diagnosedwith
PCOS using the Rotterdam criteria (n = 73) were analyzed using 16S ribosomal RNA gene sequencing.
Results: Lower a diversity was observed in women with PCOS compared with healthy women.
Women with PCOM had a change in a diversity that was intermediate between that of the other
two groups. Regression analyses showed that hyperandrogenism, total testosterone, and hirsutism
were negatively correlated with a diversity. Permutational multivariate analysis of variance in
UniFrac distances showed that hyperandrogenism was also correlated with b diversity. A random
forest identified bacteria that discriminated between healthy women and women with PCOS.
Conclusion: These results suggest that hyperandrogenism may play a critical role in altering the gut
microbiome in women with PCOS. (J Clin Endocrinol Metab 103: 1502–1511, 2018)
Polycystic ovary syndrome (PCOS) is the most com-mon endocrine disorder in women of reproductive
age, with an estimated worldwide prevalence of 5% to
15%when the Rotterdam consensus criteria are used (1).
Hyperandrogenism is a key feature of this disorder, and
heritability studies indicate that there is a strong poly-
genic component (2). PCOS can result in profound, long-
term health consequences (3). In addition to increased
risks of infertility, miscarriage, and pregnancy compli-
cations, many women with PCOS have metabolic ab-
normalities that increase their risk of developing obesity,
type 2 diabetes, and cardiovascular disease (4, 5).
A complex community of microorganisms that is
important for human health resides within the large
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intestine (the gut microbiome) (6). Correlative studies
demonstrated that the gut microbiome of individuals
with metabolic disorders such as obesity and diabetes
differs from that of healthy individuals (7–10). More
recently, two studies reported differences in the gut
microbiome of Caucasian or Han Chinese women with
PCOS, including a decrease in the overall bacterial species
richness (a diversity) of the gut microbial community and
changes in several bacterial taxa, compared with that
of healthy women (11, 12). Fecal microbiome trans-
plantation from obese humans into germ-free mice also
resulted in an obese phenotype, indicating a potential
causative role of the gut microbiome in the development
of metabolic disorders (13, 14).
Given that we previously observed changes in the gut
microbiome in a hyperandrogenic mouse model of PCOS
(15), we investigated whether changes in the gut micro-
biome in women with PCOS correlate with hyper-
androgenism or other hallmarks of PCOS. We found that
womenwith PCOShad a decrease in biodiversity in the gut
microbiome and changes in specific bacterial taxa com-
pared with healthy women. Women with polycystic
ovarian morphology (PCOM) also had a change in gut
microbial diversity that was intermediate between that of
the other two groups. Furthermore, our analyses dem-
onstrated that hyperandrogenism (total testosterone and
hirsutism) was correlated with changes in the gut micro-
biome. A better understanding of the relationship between
hyperandrogenism and the gutmicrobiome inwomenmay
lead to new therapeutic approaches for PCOS.
Subjects and Methods
Study cohort
A total of 163 premenopausal women were recruited at the
Poznan University of Medical Sciences. Using the Rotterdam
criteria, PCOS was diagnosed by the presence of at least two
of the following conditions: clinical or biochemical hyper-
androgenism (Ferriman-Gallwey score $8; testosterone level
.0.5 ng/mL), oligomenorrhea or amenorrhea (,8 cycles/y),
and polycystic ovaries. Congenital adrenal hyperplasia was
excluded on the basis of a morning follicular phase 17-
hydroxyprogesterone level ,2 ng/mL. Diabetes mellitus was
excluded on the basis of a fasting glucose level ,100 mg/dL
and a glucose tolerance test value ,200 mg/dL at 30, 60, and
90 minutes and ,140 mg/dL at 120 minutes. None of the
subjects had elevated prolactin levels, thyroid disease, or Cushing
disease. Study participants had no clinical signs or symptoms of
any other endocrinopathy, a normal baseline renal function, and
normal levels of bilirubin and aminotransferases. Exclusion
criteria were the use of oral contraceptives, other steroid hor-
mones, and metformin within the preceding 3 months. Subjects
taking antibiotics, probiotics, or laxatives were excluded. All
study participants were at least 18 years old and provided in-
formed consent. The study was approved by the institutional
review boards at the Poznan University of Medical Sciences and
the University of California, San Diego.
Sampling and laboratory measurements
The study visits took place between 8:30 and 11 AM. Clinical
assessments included determination of body mass index (BMI)
and hirsutism. Venous blood was collected after an overnight
fast, and serum was stored at 280°C until the analyses were
performed. A 2-hour oral glucose tolerance test was performed
with determinations of glucose and insulin in the fasting state as
well as after a 75-g glucose load at 30, 60, 90, and 120 minutes.
Fecal samples were collected from the rectum using a cotton
swab (CultureSwab 220135; Becton Dickinson). Samples were
stored at 280°C within 20 minutes of collection. Transvaginal
ultrasonographic evaluations were performed using the Aloka
ProSound 7 (Aloka Co. Ltd.). The ovaries were measured in
three perpendicular diameters. Ovarian volume was determined
using the prolate ellipsoid formula. Glucose levels were de-
termined using the enzymatic reference method with hexo-
kinase. Serum testosterone, luteinizing hormone (LH),
follicle-stimulating hormone (FSH), sex hormone-binding
globulin, and insulin levels were determined using electro-
chemiluminescence assays (Roche Cobas 6000 System).
DNA isolation
Rectal swab samples were shipped on dry ice to the Uni-
versity of California, San Diego and stored at280°C. Genomic
DNA was extracted from samples in a class II biological safety
cabinet using the PowerSoil DNA Isolation Kit (MoBio Lab-
oratories, Inc.). Solution C1 (60 mL) was added to the bead
beating tubes, and the cotton tips of the swabs were broken off
directly into the tubes. Tubes were vortexed at maximum speed
for 15 minutes using the PowerSoil Vortex Adaptor (MoBio
Laboratories, Inc). The remaining steps were performed as
directed by the manufacturer. Genomic DNA was quantified
using a Nanodrop 2000 spectrophotometer (Thermo Fisher
Scientific), and the DNA was stored at 280°C.
16S ribosomal RNA amplicon sequencing
For each sample, the V4 hypervariable region of the 16S
ribosomal RNA (rRNA) gene was polymerase chain reaction
(PCR) amplified with primers 515F and 806R (16). The reverse
primers contained unique 12-base-pair Golay barcodes that
were incorporated into the PCR amplicons (17). PCR param-
eters were as follows: denaturing at 94°C for 3minutes followed
by amplification for 35 cycles at 94°C for 45 seconds, at 50°C
for 60 seconds, at 72°C for 90 seconds, and with a final ex-
tension of 72°C for 10 minutes. Amplicon sequence libraries
were prepared at The Scripps Research Institute Next Gener-
ation Sequencing Core Facility, where the libraries were se-
quenced on an Illumina MiSeq as previously described (15).
16S rRNA amplicon analysis
Raw sequences were imported into QIIME 2 (v.2017.6;
https://docs.qiime2.org/2017.6/) (18) using the q2-tools-import
script, and sequences were demultiplexed using the q2-demux
emp-single script. This resulted in 5.6 million sequences with an
average of 30,000 sequences per sample. The 16S rRNA se-
quences generated in this study were deposited into the Euro-
pean Nucleotide Archive (study accession no. PRJEB22972).
DADA2 software was used to obtain a set of observed sequence
variants (SVs) (19). DADA2 uses an Illumina sequence error
correction algorithm to derive an abundance distribution of
distinct SVs, which can differ by only a single nucleotide. On the
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basis of the quality scores, the forward reads were truncated at
position 220 using the q2-dada2-denoise script. Taxonomy was
assigned using a pretrained naive Bayes classifier [Greengenes
13_8 99% operational taxonomic units (OTUs)], and the q2-
feature-classifier plug-in (20). Singletons and SVs present
in ,10% of samples were removed to minimize the effect of
spurious, low abundance sequences using the q2-feature-table
filter-features script. The resulting SVs were then aligned using
MAFFT (21), and a phylogenetic tree was built using FastTree
(22). Taxonomic distributions of the samples were calculated
using the q2-taxa-barplot script. The rectal swabs contained
bacteria representative of fecal samples, and there was no ev-
idence of contamination with oral, skin, or vaginal bacteria.
a and b diversity metrics were computed using the q2-
diversity core-metrics script at a rarefied sampling depth of
500. Rarefaction resulted in the removal of three samples (one
control and two PCOS) that had ,500 sequences per sample.
Four a diversity metrics, observed SVs, Faith phylogenetic di-
versity (PD), Shannon, and Pielou were used to estimate fecal
microbial community richness, PD, information content, and
evenness, respectively (23–25). Two outliers (both PCOS) were
identified in the measures of a diversity and removed from the
analyses. UniFrac was used to compare the similarity (b di-
versity) among the microbial communities by calculating the
shared PD between pairs of microbial communities (26). A
cluster of outliers (four control and four PCOS)was identified in
the principal coordinates analysis (PCoA) of unweighted Uni-
Frac and removed from the analyses.
Statistical analysis
Statistical calculations were performed in the RStudio sta-
tistical package (version 0.99.893). Data were tested for nor-
mality via the Shapiro-Wilk test. Variables that were not
normally distributedwere transformed or ranked.Differences in
the clinical characteristics of study participants andmicrobiome
characteristics were analyzed using one-way or multifactor
analysis of variance followed by a Tukey honest significant
difference test for multiple post hoc comparisons. Multivariable
linear regression models were generated by backward stepwise
elimination implemented in R using the “step” library. Simple
linear regression and Pearson rank correlation were also per-
formed. PCoA and canonical correspondence analysis (CCA)
plots were constructed using the phyloseqRpackage (V.1.19.1).
PCoA plots were used to represent the similarity of fecal
microbiome samples on the basis of multiple variables in the
data set, whereas CCA was used to visualize the relationship of
the fecal microbiome with specific clinical parameters. Per-
mutational multivariate analysis of variance (PERMANOVA)
used unweighted Unifrac distance measures to assess bacterial
community compositional differences and relationships to patient
clinical characteristics (999 permutations; “vegan” package).
CCA combinedwith PERMANOVAwas performed to single out
significant variables driving microbiome composition and to
orient the data for visualizing the differences among the factors of
interest. A random forest classifier (27) was implemented in R
using the “randomForest” library to identify a diversity factors
and bacterial observed SVs that discriminate between healthy
women andwomenwith PCOS. Since random forest assumes that
there are equal samples in each group, we sampled a random
subset of the samples from the women with PCOS to compare
with the control group.
Results
Clinical characteristics of study participants
Gut microbial diversity profiles were generated for a
total of 163women: 48 healthy controls, 42 with PCOM,
Table 1. Clinical Characteristics of Study Participants
Diagnosis ANOVA Tukey HSD (Adjusted for Multiple Comparisons)
Control
(n = 48)
PCOM Only
(n = 42)
PCOS
(n = 73) P Value Control vs PCOM Control vs PCOS PCOM vs PCOS
Age, y 29.4 6 4.9 29.8 6 5.3 27.4 6 4.9 0.04 0.97 0.11 0.08
BMI, kg/m2 23.7 6 4.1 22.6 6 4.2 25.6 6 6.5 0.02 0.34 0.39 0.01
Testosterone, ng/mL 0.3 6 0.1 0.3 6 0.1 0.56 6 0.2 ,0.0001 0.98 ,0.0001 ,0.0001
Free testosterone, V 0.35 6 0.2 0.3 6 0.2 0.9 6 0.5 ,0.0001 0.85 ,0.0001 ,0.0001
Hirsutism (Ferriman-
Gallwey)
2.9 6 1.3 3.5 6 1.8 8.1 6 4.3 ,0.0001 0.31 ,0.0001 ,0.0001
Menses per y 12.1 6 0.5 10.9 6 1.8 8.1 6 3.4 ,0.0001 0.07 ,0.0001 ,0.0001
LH, IU/L 7.7 6 5.8 10.8 6 14.3 11.9 6 8.4 ,0.0001 0.13 ,0.0001 0.02
FSH, IU/L 5.7 6 1.9 6.4 6 2.9 5.5 6 1.9 0.29 0.52 0.91 0.25
LH/FSH ratio 1.4 6 0.6 1.5 6 0.8 2.3 6 1.4 ,0.0001 0.59 ,0.0001 0.0006
Fasting glucose,
mmol/L
4.86 6 0.34 4.85 6 0.4 5.14 6 1.87 0.37 1 0.47 0.47
Fasting insulin,
pmol/L
48.5 6 18.5 46.6 6 21.9 61.4 6 38.2 0.05 0.83 0.2 0.06
HOMA-IR 1.75 6 0.7 1.69 6 0.84 2.27 6 1.54 0.01 0.97 0.05 0.03
Hyperandrogenism 0 0 62 ,0.0001 1 ,0.0001 ,0.0001
Oligomenorrhea 0 0 34 ,0.0001 1 ,0.0001 ,0.0001
PCOM 0 42 71 ,0.0001 ,0.0001 ,0.0001 0.39
Data are presented asmean6 standard deviation. Nonnormal datawere ranked and analyzed by one-way analysis of variance followed by the Tukey HSD
test.
Abbreviations: HSD, honest significant difference; V, Vermeulen equation.
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and 73 diagnosed with PCOS. Of the 73 women with
PCOS, 21 had all three criteria (hyperandrogenism,
oligomenorrhea, and PCOM), 39 had hyperandrogenism
and PCOM, two had hyperandrogenism and oligome-
norrhea, and 11 had oligomenorrhea and PCOM.
Table 1 summarizes the clinical characteristics of the
study participants. Compared with healthy women in the
control group and those with PCOM, the cohort of
women with PCOS had higher levels of serum total
testosterone and free testosterone as well as an in-
crease in hirsutism and a decrease in the number of
menses per year. Women with PCOS also had in-
creased levels of serum LH, an increased ratio of LH/
FSH, but no detectable change in serum FSH levels. In
addition, although fasting glucose and insulin levels
were not different, women with PCOS had higher
homeostasis model assessment of insulin resistance
(HOMA-IR) values. Although age and BMI did not
differ between controls and women with PCOS, there
was a small difference in BMI between women with
PCOM and women with PCOS.
PCOS was associated with reduced biodiversity in
the gut microbiome
In total, 481 observed SVs (analogous to OTUs) were
identified from the rectal swab samples. Women with PCOS
had reduced gut microbiome a diversity compared with
healthywomenasmeasuredbyabundance (observedSVs;P=
0.04) and PD (Faith PD; P = 0.02) [Fig. 1(a) and 1(b)].
Women with PCOM displayed an intermediate phenotype
in both observed SVs and Faith PD because the a diversity of
their gut microbiome was not statistically different from that
of healthywomenorwomenwithPCOS.WomenwithPCOS
also tended tohave lowerShannondiversity,whichaccounted
for both abundance and evenness of SVs, than controls (P =
0.1) [Fig. 1(c)]. There was no difference in the evenness of
the gut microbiome of women with PCOS compared with
that of either controls or women with PCOM [Fig. 1(d)].
Figure 1. Biodiversity of the gut microbiome was decreased in women with PCOS. Box plots of a diversity in fecal samples from healthy women
(controls; n = 47), women with PCOM (n = 41), and women diagnosed with PCOS using the Rotterdam criteria (n = 70) are shown, with
whiskers extending 1.53 past the interquartile range. (a‒d) a diversity was calculated using (a) the number of observed SVs as an estimate of
species richness, (b) Faith PD as an estimate of species richness that takes phylogenetic relationships into account, (c) Shannon as an estimate of
both species richness and evenness, and (d) Pielou as an estimate of the evenness of a community. One-way analysis of variance was performed
on ranked data with the Tukey honest significant difference post hoc test to compare means among groups. *P , 0.05.
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Higher total testosterone levels and hirsutism
correlated with lower biodiversity in the
gut microbiome
Backward stepwise regression was used to build mul-
tiple regression models for identification of clinical pa-
rameters that best predicted two measures of a diversity
(i.e., observed SVs andFaithPD). Table 2 shows the factors
that contributed to the multiple regression models. Total
testosterone level, hyperandrogenism, and number of
menses per year correlated with observed SVs in the
multiple regressionmodel, whereas total testosterone level,
hirsutism, and hyperandrogenism correlated with Faith
PD. The ratio of LH/FSH may also correlate with a di-
versity (observed SVs and Faith PD; P = 0.08). In contrast,
age, BMI, andHOMA-IRdid not correlatewitha diversity
and were not included in the models. In addition, simple
linear regression was performed on clinical or biochemical
hyperandrogenism to get a better understanding and vi-
sualization of the data. Both serum total testosterone level
and hirsutism showed negative correlations with observed
SVs (P = 0.006 and P = 0.02, respectively) and Faith PD
(P = 0.05 and P = 0.03, respectively) (Fig. 2).
Hyperandrogenism was associated with changes in
the gut microbiome
b diversity
In addition to assessing a diversity, we used un-
weighted and weighted UniFrac analyses to compare the
similarity of the gut microbial communities (b diversity)
between healthy women and women with PCOS. a di-
versity estimates the within-sample biodiversity, whereas
b diversity estimates the biodiversity between samples.
PCoA and PERMANOVA were used to analyze the re-
lationship between overall gut bacterial composition and
clinical characteristics of the study participants. Although
there was no distinct clustering between samples from
controls and those from women with PCOS [Fig. 3(a)],
PERMANOVA tests detected a highly significant effect of
hyperandrogenism (P = 0.0009) and, to a lesser extent,
diagnostic group (P = 0.08) on the microbial community
composition (Table 3). When CCA was applied to visu-
alize the relationship of the gut microbial community
structure to clinical and biochemical hyperandrogenism, a
separation between samples from controls and from
women with PCOS that correlated with hirsutism was
observed (P = 0.06) [Fig. 3(b)].
Random forest identified bacterial taxa that
distinguished between healthy women and
women with PCOS
The random forest machine learning classifier was
trained to determine how well healthy women and
women with PCOS could be predicted on the basis of a
diversity and bacteria represented by observed SVs. The
random forest had the highest accuracy in distinguishing
women with PCOS (65% accuracy) followed by controls
(50% accuracy). The variable importance by mean de-
crease in accuracy was then calculated from the random
forest model (Supplemental Fig. 1). The relative abun-
dance of the eight bacterial genera whose removal caused
the greatest decrease in model accuracy (i.e., the most
important for classification) was graphed for healthy
women andwomenwith PCOS [Fig. 3(c)]. These bacteria
included Porphyromonas spp., Bacteroides coprophilus,
Blautia spp., Faecalibacterium prausnitzii, Anaerococcus
spp., Odoribacter spp., Roseburia spp., and Rumino-
coccus bromii.
Discussion
This study demonstrated that Caucasian women di-
agnosed with PCOS using the Rotterdam criteria had a
reduction in overall species richness (a diversity) of the
gut microbiome compared with that of healthy women
and changes in the composition of the microbial com-
munity (b diversity). Interestingly, our study found that
the biodiversity of the microbiome strongly correlated
with hyperandrogenism. More specifically, observed SVs
and Faith PD were both negatively correlated with total
testosterone level and hirsutism, whereas hyper-
androgenism had a highly significant effect on the
structure of the bacterial community as measured by
Table 2. Summary of Multiple Regression Analysis
Relating Patient Parameters to a Diversity
Std. Error t Value P Value
Observed SVs
Control vs PCOM 9.61 21.49 0.13
Control vs PCOS 18.35 22.28 0.02a
Testosterone, ng/mL 24.50 22.58 0.01a
Hirsutism 1.25 21.70 0.09
Hyperandrogenism 18.67 22.28 0.02a
Menses per y 2.27 22.05 0.04a
Oligomenorrhea 16.67 21.51 0.13
LH/FSH ratio 3.20 1.75 0.08
Faith PD
Control vs PCOM 37.14 21.79 0.07
Control vs PCOS 48.13 22.55 0.01a
Testosterone, ng/mL 24.38 22.00 0.04a
Hirsutism 1.25 22.17 0.03a
Hyperandrogenism 18.43 23.25 0.001b
Menses per y 1.56 21.57 0.11
PCOM 43.77 1.42 0.16
LH/FSH ratio 3.17 1.76 0.08
Data were ranked and a backward stepwise regression was used to select
themodel that best predicted observed SVs (r=0.14) and Faith PD (r=0.16).
aP , 0.05.
bP , 0.01.
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unweighted UniFrac. We also observed an intermediate
phenotype for women with PCOM regarding gut micro-
biome a diversity, suggesting that further studies are
warranted to determine whether the gut microbiome of
womenwith PCOM is significantly altered comparedwith
that of healthy women.
a diversity metrics estimate the overall biodiversity
of a community (i.e., the bacterial species in the gut
microbiome). Compared with healthy controls, women
with PCOS had a reduced overall number of bacterial
species and lower PD (observed SVs and Faith PD),
whereas there was no difference in community evenness
(Pielou) [Fig. 1(a)‒1(d)]. This agrees with two previous
studies that found a decrease ina diversity inwomenwith
PCOS compared with healthy women (11, 12). Reduced
a diversity of the gut microbiome was also observed in
humans with metabolic diseases compared with healthy
individuals. Indeed, lower a diversity of the gut micro-
biome was consistently associated with human obesity
according to several recent meta-analyses (28–30).
In the field of ecology, species richness has been
proposed to correlate with the health of an ecosystem,
as diverse communities may increase the stability and
productivity of an ecosystem (31). In terms of the gut
microbiome, it is possible that decreased bacterial di-
versity results in changes in gut function that can exac-
erbate diseases, including PCOS, though much work
remains to be done to understand how changes in the gut
microbiome influence host physiology.
Multiple and single linear regression analyses showed
that the decrease in a diversity was associated with total
testosterone level and hirsutism [Fig. 2(a)‒2(d); Table 2].
These results concur with the negative correlation we
observed between a diversity and testosterone level in a
hyperandrogenic, letrozole-induced PCOS mouse model
(15). Interestingly, factors such as the number of menses
per year and the LH/FSH ratio also contributed to the
multiple regression models but did not have a significant
association with a diversity in the single linear regression
analysis. In contrast, free testosterone, LH, and FSH
Figure 2. A decrease in gut bacterial biodiversity correlated with an increase in testosterone level and hirsutism. (a‒d) Scatterplots and trend lines
show the relationship between testosterone and (a) observed SVs or (c) Faith PD as well as the relationship between hirsutism and (b) observed
SVs or (d) Faith PD. Results of a Pearson correlation (P value and correlation coefficient) are shown in the insets, with the gray shaded areas
indicating the 95% confidence interval for the line of best fit. Healthy women (controls; n = 47), women with PCOM (n = 41), and women with
PCOS (n = 70).
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levels, as well as age, BMI, or HOMA-IR, did not con-
tribute to the multiple regression models or correlate with
a diversity.
In addition to a diversity, our study demonstrated a
difference in the overall gut microbial composition
(b diversity) between healthy women and women with
PCOS. Our results agree with the two aforementioned
studies that demonstrated changes in b diversity between
healthy women and women with PCOS according to
unweighted Unifrac and Bray-Curtis analyses (11, 12). In
addition, using PERMANOVA, we demonstrated that
hyperandrogenism was strongly correlated with changes
in the gut microbiome (Table 3). CCA also identified a
difference between the gut microbiome of women with
Figure 3. b diversity of the gut bacterial community was influenced by hyperandrogenism (HA), and random forests identified bacterial taxa that
distinguished between healthy women and women with PCOS. (a) PCoA of b diversity (unweighted UniFrac distances) of fecal samples from
healthy women (controls; n = 43) and women with PCOS (n = 66). Proportion of variance explained by each principal coordinate (PC) axis is
denoted on the corresponding axis. Permutation analysis of variance of the unweighted UniFrac distances indicated that hyperandrogenism had
a strong influence on the gut microbial community (P = 0.0009). (b) CCA represents the relationship between b diversity and specific variables of
interest, such as HA, testosterone, and hirsutism. CCA demonstrated that changes in the gut microbial communities between healthy women
and women with PCOS correlated with hirsutism (permutation test; P = 0.06). Proportion of variance explained by each CCA axis is denoted on
the corresponding axis. The arrows represent the direction and strength of the correlation between gut microbiome composition and specific
variables of interest. (c) A random forest classifier was used to identify bacterial observed SVs that best distinguished between healthy women
(controls) and women with PCOS. The relative mean abundances (mean 6 standard error of the mean) of the top eight most discriminant
observed SVs are identified to the genus and species level when possible.
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PCOS and that of healthy women and showed that
hirsutism was associated with the observed composi-
tional differences (P = 0.06) [Fig. 3(b)]. Our results agree
with the study by Liu et al. (12), who used SparCC to
analyze the gut microbiome of Han Chinese women with
PCOS and healthy women and found that a number of
distinct bacterial OTUs correlated with both total tes-
tosterone level and hirsutism. Although one cannot infer
causation from association studies, the accumulating data
from studies of humans and rodent models suggest that
androgen levels may have a significant effect on the
composition of the gut microbiome in women with PCOS.
Kruskal-Wallis tests did not detect significant dif-
ferences between the relative abundance of specific
bacterial taxa in the gut microbiome of healthy women
compared with women with PCOS after correction for
multiple comparisons. However, a supervised learning
approach using the random forest method identified
several bacteria that distinguished the gut microbiome
of healthy women from that of women with PCOS
[Fig. 3(c)]. The relative abundance of Porphyromonas
spp., B. coprophilus, Blautia spp., and F. prausnitziiwas
consistently higher in women with PCOS, whereas
Anaerococcus spp., Odoribacter spp., Roseburia spp.,
and R. bromii were lower [Fig. 3(c)]. Porphyromonas
has been reported to increase gut permeability and
dysbiosis (32). The relative abundance ofB. coprophilus
was reported to be higher in obese individuals (33),
whereas patients with type 2 diabetes and glucose intol-
erance had greater numbers of Blautia (34). Interestingly,
F. prausnitzii is a commensal bacterium known to produce
short-chain fatty acids (SCFAs), and in several reports,
lower abundance of this bacterium was associated with
obesity and Crohn disease (35), which is opposite to the
pattern we observed in women with PCOS [Fig. 3(c)].
The four taxa identified by random forest that had
lower abundance in women with PCOS [Fig. 3(c)] are all
known to synthesize SCFAs. SCFAs are microbial me-
tabolites that have distinct physiological effects on the
host. Butyrate, in particular, is involved in a number of
beneficial processes to the host, including down-
regulation of bacterial virulence; maintenance of colonic
homeostasis, including acting as an energy source for
intestinal epithelial cells; and anti-inflammatory effects
(36). Decreased levels of certain strains of Odoribacter
and Roseburia have been associated with Crohn disease
and ulcerative colitis and were thought to increase the
host’s inflammatory response via reduced SCFA pro-
duction (37, 38). Specific strains of Anaerococcus are
more abundant in obese individuals (33), whereas
R. bromii was associated with a lower concentration of
SCFAs and insulin sensitivity (39, 40).
Conclusion
In summary, our study demonstrated that hyper-
androgenism was correlated with changes in the gut
microbiome in women with PCOS. Our findings sug-
gest that androgens may be an important factor in
shaping the gut microbiome and that changes in the gut
microbiome may influence the development and pa-
thology of PCOS. If hyperandrogenism drives the mi-
crobial composition of the gut, it would be interesting
to determine if treatment of PCOS with androgen
antagonists or oral contraceptives results in recovery of
the gut microbiome and improvement of the PCOS
metabolic phenotype. Moreover, it would be informative
to determine whether the gut microbiome of women
diagnosed with PCOS using the criteria of oligomenor-
rhea and polycystic ovaries is distinct from that of women
diagnosed with the other subtypes of PCOS that include
hyperandrogenism.
Although many studies have reported that obesity was
associated with changes in the gut microbiome, it is
noteworthy that BMI or HOMA-IR did not correlate
with changes in a or b diversity of the gut microbiome in
our study. One possible explanation is that the average
BMI of the women in this study was 24.326 0.85 kg/m2.
Further sampling of the gut microbiome of obese women
with or without PCOS could address whether obesity
and insulin resistance influence the gut microbiome in
women with PCOS. However, given variations in the
human gut microbiome, large clinical cohorts will likely
be needed to address these questions. Future studies to
determine whether specific gut bacterial species play a
causative role in PCOS will also be important in de-
termining whether probiotics are a treatment option
for PCOS.
Table 3. Summary of Permutational Analysis of
Variance Assessing the Effect of Patient Parameters
on Unweighted UniFrac Distances (b Diversity)
Mean Squares Pseudo-F P Value
Control vs PCOS 0.31 1.33 0.08
Age, y 0.22 1.01 0.42
BMI, kg/m2 0.18 0.81 0.79
Testosterone, ng/mL 0.24 1.09 0.29
Hirsutism 0.18 0.81 0.77
Menses per y 0.24 1.08 0.31
LH/FSH ratio 0.19 0.85 0.71
Fasting glucose, mmol/L 0.24 1.1 0.37
Fasting insulin, pmol/L 0.21 0.97 0.51
HOMA-IR 0.19 0.89 0.67
Hyperandrogenism 0.47 2.11 0.0009a
Oligomenorrhea 0.21 0.96 0.52
PCOM 0.20 0.95 0.52
aP , 0.001.
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Letrozole treatment of adult female mice
results in a similar reproductive phenotype
but distinct changes in metabolism and the
gut microbiome compared to pubertal
mice
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Abstract
Background: A majority of women with polycystic ovary syndrome (PCOS) have metabolic dysfunction that results
in an increased risk of type 2 diabetes. We previously developed a pubertal mouse model using the aromatase
inhibitor, letrozole, which recapitulates many of the reproductive and metabolic features of PCOS. To further our
understanding of the effects of androgen excess, we compared the effects of letrozole treatment initiated in
puberty versus adulthood on reproductive and metabolic phenotypes as well as on the gut microbiome.
Results: Letrozole treatment of both pubertal and adult female mice resulted in reproductive hallmarks of PCOS,
including hyperandrogenemia, anovulation and polycystic ovaries. However, unlike pubertal mice, treatment of
adult female mice resulted in modest weight gain and abdominal adiposity, minimal elevation in fasting blood
glucose and insulin levels, and no detectable insulin resistance. In addition, letrozole treatment of adult mice was
associated with a distinct shift in gut microbial diversity compared to letrozole treatment of pubertal mice.
Conclusions: Our results indicate that dysregulation of metabolism and the gut microbiome in PCOS may be
influenced by the timing of androgen exposure. In addition, the minimal weight gain and lack of insulin resistance
in adult female mice after letrozole treatment indicates that this model may be useful for investigating the effects
of hyperandrogenemia on the hypothalamic-pituitary-gonadal axis and the periphery without the influence of
substantial metabolic dysregulation.
Keywords: Gut microbiome, Polycystic ovary syndrome, Hyperandrogenism, Puberty
Background
Polycystic ovary syndrome (PCOS) is the most common
endocrine disorder in reproductive-aged women with an
estimated world-wide prevalence of 6–15%, but the eti-
ology of PCOS is not well understood [1]. Heritability
and twin studies have identified a strong genetic compo-
nent that is likely polygenic [2–4]. Recent genome-wide
association studies have reported multiple susceptibility
loci associated with an increased risk of developing
PCOS [5]. Environmental factors, such as prenatal ex-
posure to androgens may also play a role in the etiology
of PCOS [6]. Currently, diagnosis is made using the Rot-
terdam Consensus criteria (2003), which require at least
two of the following: hyperandrogenism, oligo- or amen-
orrhea and polycystic ovaries [1].
Studies have shown that women with PCOS often suf-
fer from profound, long-term health issues [7]. PCOS is
the leading cause of anovulatory infertility in women
and increases the likelihood of miscarriage and preg-
nancy complications [8, 9]. In addition, a majority of
* Correspondence: vthackray@ucsd.edu
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women with PCOS have abnormalities that increase
their risk of developing metabolic disease [1, 10–15]. A
large, retrospective study demonstrated that PCOS was
associated with an increased risk of obesity (16 vs. 3.7%)
and type 2 diabetes (12.5 vs. 3.8%) over a 15-year period
[16]. Studies show that hyperandrogenism is strongly
correlated with development of a metabolic phenotype.
Metabolic dysfunction occurs predominantly in women
diagnosed with hyperandrogenism and ovulatory dys-
function, independent of body mass index [17, 18].
A complex community of microorganisms (the micro-
biome) resides within the large intestine and is import-
ant for human health [19, 20]. Correlative studies have
demonstrated that the gut microbiome of individuals
with metabolic disorders, such as obesity and diabetes,
differ significantly from healthy individuals [21–25]. In
addition, mouse models of obesity are associated with
gut microbiome dysregulation [26–31]. Studies have also
shown that fecal transplantation of the gut microbiome
from obese individuals into germ-free mice results in an
obese phenotype [22, 32, 33], indicating a potential role
of the gut microbiome in the development of metabolic
disorders [34]. Recent studies indicate that changes in
the gut microbiome are associated with PCOS. Women
diagnosed with PCOS using the Rotterdam criteria were
reported to have a significant reduction in the overall
bacterial species richness (alpha diversity) of the gut mi-
crobial community and changes in the abundance of
several bacterial taxa compared to healthy women [35–
37]. Interestingly, a study from our lab also showed a
significant correlation between hyperandrogenism and
diversity of the gut microbiome, suggesting that andro-
gens may influence the composition of the gut micro-
biome in women [37].
Since hyperandrogenism is associated with PCOS, re-
searchers have created animal models to study the role
of androgens in the development and pathology of
PCOS [reviewed in [38–42]]. Several mouse models were
developed using treatment with exogenous dihydrotes-
tosterone but these models did not exhibit the elevated
LH levels associated with PCOS [43–47]. We developed
a PCOS mouse model in pubertal female mice using
treatment with the aromatase inhibitor, letrozole, to
limit the conversion of testosterone to estrogen which
results in increased testosterone and decreased estrogen
levels. This model is based on the findings that genetic
variants of the aromatase gene are associated with the
development of PCOS in women and that a higher an-
drogen/estrogen ratio is found in the ovaries of women
with PCOS [48–52]. We demonstrated that this mouse
model has many hallmarks of PCOS including hyperan-
drogenemia, elevated LH levels, acyclicity, and polycystic
ovaries [53, 54]. This model also exhibited a metabolic
phenotype including weight gain, abdominal adiposity,
dysglycemia, hyperinsulinemia, and insulin resistance
after 5 weeks of letrozole treatment [55]. Similar to
women with PCOS, we also showed that there was a sig-
nificant decrease in the alpha diversity of the gut micro-
biome in the letrozole-induced PCOS mouse model that
correlated with hyperandrogenism [54]. To gain more
insight into the effects of androgen excess, we investi-
gated whether the timing of testosterone exposure was
important for the pathophysiology of PCOS by evaluat-
ing the effects of letrozole treatment on reproductive
and metabolic phenotypes in pubertal versus adult fe-
male mice.
Results
Letrozole treatment of adult female mice resulted in
reproductive hallmarks of PCOS
In this study, we investigated whether the age at which
letrozole treatment was initiated affected development
of the PCOS phenotype in female mice (Fig. 1a). Five
weeks of letrozole treatment in pubertal and adult fe-
male mice resulted in elevated serum testosterone levels
(Fig. 1b-c). Letrozole treatment in adult female mice also
resulted in increased LH levels (Fig. 1d) and acyclicity
(Fig. 1e). Interestingly, the ovarian weight was similar in
placebo and letrozole-treated adult mice (Fig. 1f ). This is
in contrast to the increase in ovarian weight previously
observed in letrozole-treated pubertal mice [53, 54].
Similar to pubertal mice, letrozole treatment of adult
female mice resulted in ovaries with cystic follicles
and hemorrhagic cysts (Fig. 1g). Ovaries in the
letrozole-treated mice also lacked corpora lutea, indicat-
ing a lack of ovulation compared to placebo-treated
mice.
Letrozole treatment of adult female mice resulted in
minimal weight gain and abdominal adiposity after 5
weeks of treatment
Similar to previous reports [53, 54], letrozole treatment
of pubertal female mice for 2 weeks resulted in substan-
tial weight gain compared with placebo treatment, and
weight was still increased at the end of the study
(Fig. 2a). In contrast, letrozole treatment of adult female
mice resulted in a more modest weight gain after 2
weeks of treatment and weight was not statistically dif-
ferent compared to placebo-treated mice after 5 weeks
of treatment (Fig. 2a). Letrozole treatment of pubertal
female mice resulted in a significant change in abdom-
inal adiposity compared with placebo as reflected in an
increase in the weight of the parametrial fat pad relative
to total body weight (Fig. 2b). However, letrozole treat-
ment of adult mice did not result in increased abdominal
adiposity compared with placebo-treated mice (Fig. 2b).
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Fig. 1 Letrozole treatment of adult female mice resulted in reproductive hallmarks of PCOS. Letrozole (LET) treatment was initiated at 8 weeks of
age in the adult PCOS mouse model compared to 4 weeks of age in the pubertal PCOS mouse model (a). LET treatment of pubertal and adult
female mice for 5 weeks resulted in elevated serum testosterone (b-c). LET treatment of adult female mice resulted in elevated LH levels (d), and
decreased cyclicity as measured by percentage (%) of mice that had an estrous cycle between 4 and 5 weeks of treatment (e). In contrast to
pubertal mice, LET treatment of adult female mice did not result in an increase in ovarian weight (f). Pubertal PCOS model (n = 24 placebo (P), n
= 22 LET; adult PCOS model (n = 16 P, n = 14 LET). Student t-test; * p < 0.05. LET treatment of adult female mice resulted in ovaries lacking corpora
lutea (CL) and containing cystic follicles (CF) and hemorrhagic cysts (HC) compared to placebo-treated mice (g)
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Letrozole treatment of adult female mice resulted in less
elevation of fasting blood glucose and insulin levels and
did not result in insulin resistance
Both the pubertal and adult PCOS mouse models dis-
played dysglycemia and hyperinsulinemia but the pheno-
type was more modest in the adult model. Letrozole
treatment of pubertal female mice resulted in elevated
fasting blood glucose (FBG) levels and a 3-fold increase
in fasting blood insulin levels (Fig. 3a-b). In contrast,
letrozole treatment of adult female mice resulted in a
slight but statistically significant increase in FBG and a
2-fold increase in insulin levels. There was no significant
difference in the response to exogenous glucose in a glu-
cose tolerance test in mice treated with letrozole com-
pared to placebo in either the pubertal or adult PCOS
mouse models (data not shown). Finally, the pubertal
PCOS mouse model displayed signs of insulin resistance
compared to placebo-treated mice while the adult PCOS
mouse model remained insulin sensitive (Fig. 3c).
Letrozole treatment of adult female mice was not
associated with a strong correlation between alpha
diversity and time
Gut microbial diversity profiles were generated from 84 fecal
samples taken prior to and during 5weeks of placebo or
letrozole treatment (weeks 0–5). Sequences collected before
placebo and letrozole treatment were compared for both the
pubertal and adult mouse models. No significant difference
in alpha and beta diversity was observed between the two
treatment groups at time 0, indicating that the gut micro-
biomes of the groups were similar prior to treatment for
both the pubertal and adult cohort (Additional file 1: Figure
S1). Similar to a previous study in pubertal mice [54],
placebo-treated adult mice showed a strong positive correl-
ation between alpha diversity and time as measured by spe-
cies richness and phylogenetic diversity but not evenness of
their gut communities (Fig. 4a, c, e). In contrast, letrozole
treatment of adult mice was associated with a relatively
weak positive correlation between alpha diversity and time
(Fig. 3b, d, f). To examine this further, we evaluated whether
there was a significant difference amongst the time points
using a repeated measures (RM) ANOVA. RM-ANOVA
found a highly significant effect of time on species richness
and phylogenetic diversity in placebo-treated mice but no
difference in letrozole-treated mice.
Letrozole treatment of adult female mice resulted in
changes in gut microbiome beta diversity
UniFrac analyses were used to compare the similarity
amongst gut microbial communities (beta diversity) in
fecal samples from placebo versus letrozole–treated
adult female mice. When all post-treatment data points
were combined together, clustering of the data based on
treatment was observed with unweighted UniFrac
(Fig. 5a). When the samples were separated by the indi-
vidual time points (Fig. 5b-f ), Analysis of Similarity
(ANOSIM) tests found a difference in the overall bacter-
ial community composition of the gut microbiome be-
tween placebo and letrozole–treated adult female mice
at weeks 4 and 5 post-treatment (p = 0.01 and p = 0.03
respectively). We also observed similar results using
weighted UniFrac (data not shown).
A
B
Fig. 2 Five weeks of letrozole treatment of adult female mice did
not result in substantial weight gain or abdominal adiposity. The
phenotype of pubertal (4 week-old) versus adult (8 week-old) female
mice treated with placebo (P) or letrozole (LET) for 5 weeks was
compared. In contrast to pubertal mice, 5 weeks of LET treatment of
adult female mice did not result in a significant increase in weight
(a) or abdominal adiposity as measured by parametrial fat relative to
total body weight (b). Pubertal PCOS model (n = 24 P, n = 22 LET;
adult PCOS model (n = 16 P, n = 14 LET). Student t-test, * p < 0.05
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Distinct bacterial genera discriminated between placebo
and letrozole treatment in the pubertal and adult PCOS
mouse models
In addition to studying changes in alpha and beta di-
versity, we also investigated whether the age at which
letrozole treatment was initiated was important for
changes in the taxonomic composition of the gut
microbiome. We combined the post-treatment data
(weeks 1–5) from placebo and letrozole-treated mice
in the pubertal and adult mouse models. Based on
the Greengenes taxonomic database, we identified a
total of 10 bacterial phyla and 51 bacterial genera in
the four different groups. Similar to our previous
study [54], the majority of Operational Taxonomic
Units (OTUs) in the adult mouse fecal samples were
identified as Bacteriodetes or Firmicutes (~ 84–95%).
We used RM-ANOVA to determine if the mean rela-
tive abundances of specific bacterial genera were dif-
ferent in the gut microbiome of placebo versus
letrozole-treated mice in the pubertal and adult
mouse models. A heatmap was generated to represent
the relative abundance of 9 different bacterial genera
that changed significantly with letrozole treatment
(FDR-corrected p < 0.05) in the pubertal mouse model
(Fig. 6a). Letrozole treatment of pubertal female mice
resulted in higher relative abundances of Coprococcus,
Allobaculum, Bifidobacterium, and an undescribed
genus belonging to the Ruminococcaceae, as well as
a lower abundance of AF12, Dehalobacterium, taxa
belonging to the uncultured order YS2, and unde-
scribed genera of Peptococcaceae and Bacteroidales
(Fig. 6a).
In contrast to the pubertal mice, letrozole treat-
ment of adult female mice resulted in changes in the
mean relative abundance of a distinct set of 8 bac-
terial genera (FDR-corrected p < 0.05). With the ex-
ception of uncultured members of the genus-level
CF231 group, the rest of the genera from the Bacter-
oidetes phylum increased with letrozole treatment in
Fig. 3 Five weeks of letrozole treatment of adult female mice
resulted in a minimal increase in fasting blood glucose and insulin
levels and did not result in insulin resistance. The metabolic
phenotype of pubertal (4 week-old) versus adult (8 week-old) female
mice treated with placebo (P) or letrozole (LET) for 5 weeks was
compared. LET treatment of adult female mice resulted in reduced
fasting blood glucose (FBG) or insulin levels compared to pubertal
mice (a-b). Unlike pubertal female mice, LET treatment of adult
female mice for five weeks did not result in insulin resistance (c).
Pubertal PCOS model (n = 24 P, n = 22 LET; adult PCOS model (n = 8
P, n = 8 LET). Student t-test or two-way repeated-measures ANOVA
with post-hoc Student t-tests to directly compare P versus LET at
specific time points were performed; * p < 0.05
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adult female mice, including Prevotella, an uncul-
tured genus within Parabacteroides and a genus-level
group within the S24–7 family (Fig. 6c). Letrozole
treatment of adult mice also resulted in a higher
relative abundance of genera from Lachnospiraceae,
Ruminococcaceae, and Peptococcaceae, as well as a
lower abundance of Lactobacillus (Fig. 6c).
Random Forest classifier identified bacterial genera
predictive of placebo and letrozole treatment in the
pubertal and adult PCOS mouse models
The Random Forest (RF) classifier was trained to deter-
mine how well placebo or letrozole treatment could be
predicted based on bacterial relative abundances in the
two models (pubertal and adult). Forty-five of the 51
A B
C D
E F
Fig. 4 Letrozole treatment of adult female mice did not result in a strong correlation between time and alpha diversity of the gut microbial
community. Chao 1 species richness estimate per sample at each collection time for placebo (a) and letrozole-treated adult female mice (b), (n =
8 placebo, n = 6 letrozole). Faith’s phylogenetic diversity (PD) estimate per sample at each collection time for placebo (c) and letrozole-treated
adult female mice (d). Equitability (evenness) estimate per sample at each collection time point for placebo (e) and letrozole-treated mice (f). Line
of best fit along with results of linear regression (LM) and repeated measures (RM) ANOVA are shown in box inset
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total bacterial genera identified in the four different
groups were used for RF classification (six were excluded
due to low relative abundances). Our results showed that
RF predicted treatment category in the pubertal group
with 78.5% accuracy while it predicted treatment cat-
egory in the adult group with 84% accuracy (Table 1).
Variable importance by mean decrease in accuracy was
calculated for the RF models. Figure 6 b and d illustrate
10 bacterial genera whose removal caused the greatest
decrease in model accuracy (i.e. the most important for
classification) in the pubertal and adult mouse models
respectively. In the pubertal model, the removal of
Coprococcus, Allobaculum, AF12, Mucispirillum, Rose-
buria, Sutterella, and an unknown genus from Bacteroi-
dales had the greatest impact on classification (mean
decrease accuracy > 8; Fig. 6 b). In the adult mice, the
A B
C D
E F
Fig. 5 Letrozole treatment of adult female mice resulted in a significant shift in the beta diversity of the gut microbiome. Principal Coordinates
Analysis (PCoA) of unweighted UniFrac for samples collected post-treatment (weeks 1–5) were compared between placebo (n = 8) and letrozole-
treated (n = 6) mice (a). Proportion of variance explained by each principal coordinate axis is denoted in the corresponding axis label. Samples
from placebo- and letrozole-treated mice were then compared for each time point (b-f). Results of Analysis of Similarity (ANOSIM) tests are
shown in the box inset
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removal of Lactobacillus, CF231 and Parabacteriodes
caused the greatest decrease in prediction accuracy
(mean decrease accuracy > 8; Fig. 6 d).
Discussion
Our study demonstrated that initiation of letrozole
treatment during puberty or adulthood in female mice
resulted in reproductive hallmarks of PCOS, including
elevated testosterone levels, anovulation and ovaries
with cystic follicles. This suggests that the timing of
androgen exposure (puberty versus adulthood) may
not be important for development of the PCOS re-
productive phenotype. On the other hand, our study
did find a clear divergence between the metabolic
phenotypes of the pubertal and adult mouse models.
Similar to previously published studies [53 , 54 ], letro-
zole treatment in pubertal female mice resulted in
multiple metabolic features of PCOS, including obes-
ity, abdominal adiposity, hyperinsulinemia, and insulin
resistance. On the other hand, letrozole treatment in
adult female mice did not result in substantial weight
gain, abdominal adiposity or insulin resistance, indicating
A B
C D
Fig. 6 Repeated measures analysis of variance and Random Forest classification identified distinct bacteria associated with letrozole treatment in
the pubertal versus adult PCOS mouse model. Repeated measures analysis of variance (corrected for multiple comparisons via FDR) was used to
determine whether the abundance of specific bacterial genus differed in placebo versus letrozole-treated pubertal or adult mice. A heatmap was
generated for the bacterial genera that had a FDR adjusted p-value of < 0.05 and mean taxa abundance above 0.001 (a, c). The Random Forest
classifier was used to identify bacterial genera that distinguished between placebo and letrozole treatment in pubertal or adult female mice (b,
d). The top ten most discriminant bacterial genera in the models were displayed in the variable importance plots using a total of forty-five
genera in the analysis. An increase in mean decrease accuracy reflects the prediction strength of the variable in classifying the different
treatment groups
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that androgen exposure is not sufficient to induce the full
PCOS-like metabolic phenotype in adult female mice.
Interestingly, studies using post-natal treatment with
DHT to create a hyperandrogenic mouse model observed
a similar pattern: the metabolic phenotype depended on
when DHT treatment was initiated. Compared with
placebo-treated mice, female mice treated with DHT start-
ing at 3 weeks of age gained significantly more weight, had
greater levels of abdominal adiposity and were glucose in-
tolerant [43, 47]. In contrast, while female mice treated
with DHT in adulthood had impaired glucose tolerance,
they did not become obese or display increased abdominal
adiposity [56].
Our results also suggest that the timing of excess an-
drogen exposure may be an important component in the
development of the PCOS metabolic phenotype. Since
PCOS often manifests in the early reproductive years,
puberty has been suggested to be a critical developmen-
tal time period for the development and pathology of
PCOS [6, 57]. Indeed, PCOS has been hypothesized to
originate from abnormal pubertal development due to a
lack of transition from an androgen-dominated state in
early puberty to an estrogenic state in late puberty [58,
59]. Puberty is a time of considerable hormonal and
metabolic change, including an increase in insulin resist-
ance [60]. Although physiological insulin resistance is
common in healthy adolescents, it usually resolves to
prepubertal levels in adulthood [61]. Pubertal insulin re-
sistance has been reported to increase the risk of devel-
oping type 2 diabetes along with accelerating the
complications of diabetes [62–65]. Thus, it is possible
that insulin resistance and the hyperinsulinemia that oc-
curs during puberty may also contribute to the risk of
developing obesity and metabolic dysfunction in PCOS.
Another factor that changes during the transition from
childhood to adulthood is the gut microbiome. Studies
have shown that children or adolescents have a distinct
gut microbial community compared to adults [66, 67].
Moreover, prepubertal mice were reported to have a dif-
ferent gut microbiome than adult mice [68, 69]. Studies
in humans and mice have shown a strong positive asso-
ciation between gut bacterial alpha diversity and age, in-
dicating that the complexity of the gut microbiome
increases as the host ages [70–72]. In contrast to pla-
cebo, there was no significant effect of time on alpha di-
versity in letrozole-treated mice when the data was
adjusted for within subject error using RM-ANOVA
(Fig. 4) [54]. With regards to beta diversity, letrozole
treatment of both pubertal and adult female mice re-
sulted in a distinct shift in the gut microbial composition
(Fig. 5). However, closer examination of the types of bac-
teria that changed after letrozole treatment showed that
the taxa driving the shift in beta diversity were quite dis-
tinct in the two mouse models (Fig. 6).
Letrozole treatment initiated during puberty resulted
in changes in the abundances of bacterial genera previ-
ously reported to be altered in diet-induced obesity
mouse models. In the pubertal model, RF and statistical
analysis of relative bacterial abundances determined that
Coprococcus, Allobaculum and an unknown genus from
Bacteroidales differentiated the gut microbiomes of
placebo and letrozole-treated mice (Fig. 6a and b).
Significant differences were also observed in the relative
abundance of Bifidobacterium, reported to have
strain-specific effects on weight gain in rodents [73], as
well as Dehalobacterium and unknown genera belonging
to the Rikenellaceae and Ruminococcaceae families, all
of which have been associated with obesity [28, 74–77].
The genus with the strongest effect on RF classification,
namely Coprococcus, was previously reported to be more
abundant in obese individuals [78, 79], in agreement
with the higher levels observed after letrozole treatment
in pubertal mice. The second most important genus in
terms of classification, Allobaculum, was reported to be
lower in the gut of obese mice fed a high-fat diet [80,
81], in contrast to the increase in Allobaculum observed
after letrozole treatment.
In comparison to pubertal mice, letrozole treatment of
adult female mice had a distinct impact on the compos-
ition of the gut microbial community. With the excep-
tion of a genus within the Peptococcaceae, the bacterial
genera most affected by letrozole treatment in adult fe-
males were not altered in pubertal mice and vice versa
(Fig. 6a, c). It should be noted that the genera that chan-
ged in the pubertal and adult female mice after letrozole
treatment were present at both ages, indicating that the
differential effects of letrozole treatment in the two
models was not due to the absence of specific bacteria.
The most striking difference in letrozole treatment of
adult female mice was the importance that Lactobacillus,
Parabacteroides and the uncultured Paraprevotellaceae
group CF231 played in classifying the treatment groups
(Fig. 6d). The mean relative abundance of these bacteria
changed significantly after letrozole treatment in adult
Table 1 Classification error rates carried out using Random
Forest classifiers composed of 500 trees
Predicted classes Classification
error rates
OOB
estimate
of error
rate
Accuracy
Placebo Letrozole
Pubertal 21.5% 78.5%
Placebo 32 7 0.18
Letrozole 10 30 0.25
Adult 16.0% 84.0%
Placebo 30 1 0.03
Letrozole 7 13 0.35
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female mice (Fig. 6c). This is in contrast to the increased
abundance of some Lactobacillus species observed in
obese humans [82–84], though direct comparisons are
difficult since there may be strain-specific effects of
Lactobacillus on weight gain [85]. While CF231 has not
been described in much detail, members of the Parapre-
votellaceae are found in the gut of many mammals [86,
87] and have been suggested to be involved in the deg-
radation of plant polysaccharides into short chain fatty
acids [88]. Parabacteroides are also known to metabolize
non-digestible carbohydrates, but the increase in Para-
bacteroides relative abundance after 5 weeks of letrozole
treatment contrasts with the decrease observed in mice
fed a high-fat diet [27, 89].
Conclusions
In summary, our study demonstrated that the timing of
androgen exposure may be important for development
of the PCOS metabolic phenotype and associated
changes in the gut microbiome. While letrozole treat-
ment of female mice during puberty and in adulthood
both resulted in reproductive hallmarks of PCOS, in-
cluding hyperandrogenemia, anovulation and polycystic
ovaries, letrozole treatment in adulthood did not result
in the weight gain, abdominal adiposity or insulin resist-
ance observed in the pubertal PCOS mouse model. In
addition, letrozole treatment in adulthood resulted in
distinct changes in the gut microbiome, particularly in
Lactobacillus. Although evidence is accumulating that
changes in steroid hormones are associated with an al-
tered gut microbiome [90], the mechanisms involved in
steroid hormone/gut microbe interactions are currently
unknown. Future studies investigating whether steroid
hormones regulate the gut microbiome through actions
in the gastrointestinal tract, immune system or other tis-
sues will begin to address the mechanisms involved.
Given that many of the previous studies that report an
association of specific bacterial genera with obesity in
humans and high fat diet-induced mouse models are
contradictory, it is possible that these results are due to
modulation of specific bacterial species and strains
within genera. Future studies should employ higher reso-
lution methods such as metagenomic sequencing or
quantitative PCR to fully understand the effects of
hyperandrogenism on the gut microbiome. Moreover,
since many studies of the role of the gut microbiome in
obesity are confounded by the effect of diet on the
microbiome, the letrozole-induced PCOS mouse model
provides an opportunity to study the effects of androgen
excess on the gut microbiome and metabolism in a
diet-independent setting, since food intake is not altered
by letrozole treatment [55]. Moreover, the adult PCOS
mouse model can be used to study the effects of hyper-
androgenism in female mice without the confounding
variable of insulin resistance. Further studies addressing
whether the gut microbiome plays a causal role in the
development of PCOS or if manipulation of the gut
microbiome can improve the PCOS phenotype will be
informative. In addition, prospective studies with adoles-
cent girls may be crucial to understand the etiology and
development of PCOS, particularly the metabolic dysreg-
ulation and changes in the gut microbiome associated
with this disease.
Methods
PCOS mouse model
C57BL/6NHsd female mice purchased from Envigo
were housed in a vivarium for one week under spe-
cific pathogen-free conditions with an automatic 12
h:12 h light/dark cycle (light period: 06.00–18.00) and
ad libitum access to water and food (Teklad Global
18% Protein Extruded Diet, Envigo). Prior to the be-
ginning of the study, the mice were sorted by weight
to ensure that the starting weight was similar between
the two treatment groups. To establish the pubertal
or adult PCOS models, 4 or 8 week-old female mice,
respectively were implanted subcutaneously with a
placebo or 3 mg letrozole pellet (3 mm diameter; In-
novative Research of America) that provided a slow,
constant release of letrozole (50 μg/day) over 5 weeks.
For the duration of the experiment, the mice were
housed 2 per cage: 2 placebo or 2 letrozole-treated
mice. Placebo and letrozole-treated mice were not
housed together to avoid the influence of coprophagy
on the PCOS mouse model. At the end of the study,
the mice were sacrificed using 2.5% isoflurane deliv-
ered with a precision vaporizer followed by a physical
method of euthanasia.
Analysis of reproductive and metabolic phenotype
The mice were weighed weekly. The stage of the estrous
cycle for placebo and letrozole-treated mice was deter-
mined from the predominant cell type in vaginal epithe-
lium smears obtained during weeks 4–5 of treatment.
After 5 weeks of placebo or letrozole treatment, the mice
were fasted for 5 h and blood from the tail vein was col-
lected to measure fasting insulin levels. Blood glucose
was measured using a handheld glucometer (One Touch
UltraMini, LifeScan, Inc) and an intraperitoneal (IP) in-
sulin tolerance test (ITT) was performed. Tail vein blood
glucose was measured just before (time 0) an IP injec-
tion of insulin (0.75 U/kg in sterile saline; Humulin R
U-100, Eli Lilly) was given and at 15, 30, 45, 60, 90, and
120 min post injection.
At the end of the experiment, blood was collected
from the posterior vena cava, parametrial fat pads were
dissected and weighed, and the ovaries were dissected,
weighed, fixed in 4% paraformaldehyde at 4 °C overnight,
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and stored in 70% ethanol before processing for hist-
ology. Paraffin-embedded ovaries were sectioned at
10 μm and stained with hematoxylin and eosin (Zyagen).
Serum testosterone were measured using a mouse
ELISA (range 10–800 ng/dL) while LH levels were mea-
sured using a radioimmunoassay (range 0.04–75 ng/mL)
by the University of Virginia Center for Research in
Reproduction Ligand Assay and Analysis Core Facility.
Serum insulin was measured using a mouse ELISA
(ALPO) by the University of California, Davis Mouse
Metabolic Phenotyping Center. The data from four mice
in the pubertal and adult letrozole-treated groups were
removed from the analyses because these mice did not
have a significant elevation in serum testosterone when
compared to the average of the placebo-treated mice.
The analysis of the reproductive and metabolic pheno-
types was performed with data from 2 unpublished co-
horts of the adult PCOS model (total n = 16 placebo, n
= 14 letrozole) and 3 cohorts of the pubertal PCOS
model (total n = 24 placebo, n = 22 letrozole) including 2
unpublished and 1 previously published cohort [54]. Dif-
ferences between placebo and letrozole treatment were
analyzed by Student t-test or two-way repeated measures
ANOVA followed by post-hoc comparisons of individual
time points.
Fecal sample collection and DNA isolation
Fecal samples were collected from one cohort of
8-week-old female mice (n = 8/group) prior to treatment
with placebo or letrozole and once per week thereafter
for 5 weeks. Fecal samples were frozen immediately after
collection and stored at − 80 °C. Bacterial DNA was ex-
tracted from the fecal samples using the MoBio Power-
Soil DNA Extraction Kit following the manufacturer’s
protocol, and the DNA was stored at − 80 °C.
16S rRNA amplicon sequencing
The V4 hypervariable region of the 16S rRNA gene was
PCR amplified with primers 515F (GTGCCAGCMGCCG
CGGTAA) and 806R (GGACTACHVGGGTWTCTAAT)
[91]. The reverse primers contained unique 12 base pair
Golay barcodes that were incorporated into the PCR
amplicons [92]. The barcoded primers allowed for pooling
of multiple PCR amplicons in a single sequencing run.
Thermocycling parameters were as follows: denaturing at
98 °C for 2min followed by amplification for 35 cycles at
98 °C for 30 s, 50 °C for 30 s and 72 °C for 60 s, and a final
extension of 72 °C for 10min. The resulting amplicons
were submitted to The Scripps Research Institute Next
Generation Sequencing Core Facility where they were
cleaned using Zymo DNA Clean & Concentrator™-25 col-
umns, quantified using a Qubit Flourometer (Life Tech-
nologies) and pooled. Pooled PCR products were size
selected on a 2% agarose gel (290–350 bp), purified using
a Zymoclean™ Gel DNA recovery kit and used to prepare
sequencing libraries following the recommended Illumina
protocol involving end-repair, A-tailing and adapter
ligation. The DNA library was then size selected on a 2%
agarose gel (410–470 bp), cleaned using the Agencourt
SPRI system (Beckman Coulter, Inc.) and PCR amplified
with HiFi Polymerase (Kapa Biosystems) for 12 cycles.
The amplified DNA products were again size selected on
a 2% agarose gel and purified using the Zymoclean™ Gel
DNA recovery kit. The purified DNA library was quanti-
tated, denatured in 0.1 N NaOH and diluted to a final con-
centration of 5 pM before being loaded onto the Illumina
single read flow-cell for sequencing on the Illumina MiSeq
system along with 4 pM PhiX control library.
16S rRNA gene sequence analysis
16S rRNA sequences for the adult mice were
de-multiplexed using the Quantitative Insights Into Mi-
crobial Ecology (QIIME v.1.9.1, http://www.qiime.org)
pipeline [93] using the default split_libraries.py script
parameter [94]. This resulted in approximately 4.3 mil-
lion Illumina sequences across all samples with an aver-
age of 50,000 sequences per sample. Sequences from
two mice in the letrozole-treated group were removed
from the analysis because these mice did not have a sig-
nificant elevation in serum testosterone levels compared
to the average of the placebo-treated mice. The 16S
rRNA gene sequencing quality control and analysis for
the samples from the adult mice followed the same pipe-
line as the samples in a previously published study with
placebo or letrozole-treated pubertal female mice [54].
Sequences were clustered using the pick_de_novo_o-
tus.py script with usearch [95]. Sequences were assigned
to OTUs with an assumed 97% threshold of pairwise
identity for bacterial species by comparison with the
Greengenes reference database [96] using the RDP clas-
sifier [97]. Before performing downstream analysis, sin-
gletons and OTUs present in less than 25% of the
samples were discarded from the database to minimize
the effect of spurious, low abundance sequences using
the filter_otus_from_otu_table.py script. Sequences were
then aligned using PyNast [93] and a phylogenetic tree
constructed using FastTree [98]. The alpha_diversity.py
script was used to estimate several different attributes of
alpha diversity. Species richness was estimated using
Chao1 to define the total number of unique species in a
community [99]. Faith’s Phylogenetic Diversity was used
to measure the phylogenetic diversity of a community by
calculating the total branch lengths on a phylogenetic
tree of all members of the community [100]. Evenness
was estimated using the Equitability index [101]. The
beta_diversity_through_plots.py script was used to com-
pute weighted and unweighted UniFrac distances [102].
The smaller the UniFrac distance between two microbial
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communities, the more similar the communities are in
their overall diversity. The weighted UniFrac distance
metric incorporates the abundance of specific taxa in
each community into the UniFrac distance calculation
while unweighted UniFrac ignores abundance informa-
tion. Taxonomic distributions across sample categories
were calculated (from phylum to genus) using the sum-
marize_taxa_through_plots.py script. Several bacterial
genera such as Anaeroplasma and an unknown Entero-
bacteriaceae were excluded from the analysis because of
extremely low abundance, suggesting that they may have
been artifacts. Sequences from placebo-treated samples
collected during week 5 (9 weeks of age) of the pubertal
cohort were compared to samples collected from week 1
(9 weeks of age) from the adult cohort. No significant
difference in alpha and beta diversity was observed be-
tween the two cohorts, indicating that the gut micro-
biome at the end of placebo treatment in the pubertal
cohort was similar to the gut microbiome at the begin-
ning of placebo treatment in the adult cohort.
Statistical analysis
Pearson’s product-moment correlation was performed
when analyzing alpha diversity over time using the RStu-
dio statistical package (version 0.99.893). RM-ANOVA
was used to model alpha diversity measures accounting
for within subject error. Two-dimensional PCoA plots
were constructed using the make_2d_plots.py script in
QIIME. ANOSIM tests for weighted and unweighted
UniFrac distances between treatments were performed
using the compare_categories.py script. The biom table
of post treatment samples (weeks 1–5) from the adult
study was merged with the biom table from the pubertal
study, resulting in approximately 6.2 million sequences
from 170 samples (pubertal = 100 samples; adult = 70
samples). The merged dataset was used to compare dif-
ferences among treatment group and developmental
stage. RM-ANOVA adjusting for within subject error
(corrected for multiple comparisons via FDR) was used
to determine whether the abundance of specific bacterial
genus differed between treatments. The RF supervised
machine-learning classifier was used to determine how
well a given set of factors (e.g. bacterial genera) classified
discrete categories and which factors were most import-
ant for the classification [70, 116]. RF was implemented
in R using the “randomForest” library, and was used to
identify bacterial genera that differentiated placebo and
letrozole treatment within pubertal or adult mice.
Additional file
Additional file 1: Figure S1. No differences in gut microbial
community diversity between placebo and letrozole-treated mice were
observed prior to treatment. No significant differences in gut microbiome
alpha diversity (Faith’s PD) between placebo- and letrozole-treated mice
were observed prior to treatment (week 0) in the pubertal (placebo n =
10, letrozole n = 10) (A) or adult (placebo n = 8, letrozole n = 6) (B) model.
Similarly, no differences in beta diversity (unweighted UniFrac) were ob-
served between placebo- and letrozole-treated mice prior to treatment in
the pubertal (C) or adult model (D). Student t-test was used to compare
alpha diversity between groups and Analysis of Similarity (ANOSIM) test
was used to compare beta diversity between groups. (PDF 1335 kb)
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Exposure to a HealthyGutMicrobiome Protects Against
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Polycystic ovary syndrome (PCOS) is a common endocrine disorder affecting ;10% to 15% of
reproductive-agedwomenworldwide. Diagnosis requires two of the following: hyperandrogenism,
oligo-ovulation or anovulation, and polycystic ovaries. In addition to reproductive dysfunction,
many women with PCOS display metabolic abnormalities associated with hyperandrogenism.
Recent studies have reported that the gut microbiome is altered in women with PCOS and rodent
models of the disorder. However, it is unknown whether the gut microbiome plays a causal role in
the development and pathology of PCOS. Given its potential role, we hypothesized that exposure
to a healthy gut microbiome would protect against development of PCOS. A cohousing study was
performed using a letrozole-induced PCOS mouse model that recapitulates many reproductive and
metabolic characteristics of PCOS. Because mice are coprophagic, cohousing results in repeated,
noninvasive inoculation of gut microbes in cohoused mice via the fecal-oral route. In contrast to
letrozole-treated mice housed together, letrozole mice cohoused with placebo mice showed sig-
nificant improvement in both reproductive and metabolic PCOS phenotypes. Using 16S rRNA gene
sequencing, we also observed that the overall composition of the gut microbiome and the relative
abundance of Coprobacillus and Lactobacillus differed in letrozole-treated mice cohoused with
placebomice comparedwith letrozolemice housed together. These results suggest that dysbiosis of
the gutmicrobiomemay play a causal role in PCOS and that modulation of the gut microbiomemay
be a potential treatment option for PCOS. (Endocrinology 160: 1193 –1204, 2019)
P olycystic ovary syndrome (PCOS) is a common en-docrine disorder affecting ;10% to 15% of women
worldwide (1).Diagnosis of PCOS, based on theRotterdam
Consensus criteria (2003), requires two of the following:
hyperandrogenism, oligomenorrhea or amenorrhea, and
polycystic ovaries. PCOS is the leading cause of anovula-
tory infertility in women, and women with PCOS also have
an elevated likelihood of miscarriage and pregnancy
complications (1–3). Although it is often perceived as a
reproductive disorder, PCOS is also a metabolic disorder.
Women with PCOS have an elevated risk of developing
obesity, type 2 diabetes, hypertension, and nonalcoholic
fatty liver disease (2, 4, 5). PCOS-related metabolic dys-
function is associated with hyperandrogenism and occurs
irrespective of body mass index (6, 7). Although studies
indicate that androgen excess is an important contributor
to metabolic dysregulation in women with PCOS, the
mechanisms that lead to obesity and insulin resistance in
PCOS are not well understood. Although genetic and en-
vironmental factors undoubtedly influence the development
and pathology of PCOS (6, 8–10), it is worth exploring
whether gut microbes contribute to this disorder.
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phylogenetic diversity; PERMANOVA, permutational multivariate analysis of variance; SV,
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Studies over the past decade have shown that the
gastrointestinal tract harbors a complex microbial eco-
system (the gut microbiome) that is important for human
health and disease (11, 12). Gut microbes offer many
benefits to the host, including protection against path-
ogens and regulation of host immunity and the integrity
of the intestinal barrier (13–15). The gut microbiome is
also involved in the production of short-chain fatty acids
via fermentation of dietary fibers, production of essential
vitamins such as folic acid and B12, and modification of
bile acids, neurotransmitters, and hormones (16, 17).
Studies have also shown that changes in the gut micro-
biome are associated with metabolic disorders such as
obesity and type 2 diabetes (18, 19). Moreover, studies
have reported that transplantation of stool from obese
donors into germ-free mice results in an obese phenotype
(20), suggesting that the gut microbiome may play a
causative role in metabolic dysregulation. These trans-
plantation studies were complemented with cohousing
studies that took advantage of the fact that, because mice
are coprophagic, cohousing provides a means for re-
peated, noninvasive microbial inoculation. Cohousing
germ-free mice transplanted with stool from obese do-
nors with germ-free mice transplanted with stool from
lean donors was shown to protect the mice transplanted
with obese donor stool from developing obesity (20–22).
Altogether, these studies suggest that modulation of the
gut microbiome may be a potential treatment option for
metabolic disorders.
With regard to PCOS, several recent studies reported
that changes in the gut microbiome are associated with
PCOS (23–26). These studies detected lower a-diversity
and differences in the relative abundances of specific Bac-
teroidetes and Firmicutes in women with PCOS compared
with controls (23–25). In particular, changes in the relative
abundance of bacterial genera from the Bacteroidaceae,
Clostridaceae, Erysipelotrichidae, Lachnospiraceae, Lac-
tobacillaceae, Porphyromondaceae, Ruminococcaceae, and
S24-7 families were observed in several studies. In addition,
changes in the gut microbiome correlated with hyper-
androgenism (23–25), suggesting that testosterone may
influence the composition of the gutmicrobiome inwomen.
In addition to studies in humans, several studies reported a
significant association between the gut microbiome and
PCOS in rodentmodels (27–30). Because the rodentmodels
are diet independent, these studies suggest that the mech-
anisms that result in an altered gutmicrobiome in PCOS are
distinct from diet-induced effects on the gut microbiome
observed in high-fat diet–induced obesity models. Overall,
these studies indicate that the gut microbiome of women
with PCOS differs significantly from that of healthy women
and suggest that a microbial imbalance or “dysbiosis” in
the gut may contribute to the pathology of PCOS.
We previously developed a PCOS mouse model that
uses treatment with letrozole, a nonsteroidal aromatase
inhibitor, to increase testosterone levels and decrease
estrogen levels by inhibiting the conversion of testos-
terone to estrogen (31). Letrozole treatment of pubertal
female mice results in reproductive hallmarks of PCOS
including hyperandrogenism, acyclicity, polycystic ova-
ries, and elevated LH levels (31). This model also ex-
hibits metabolic dysregulation similar to the phenotype
in women with PCOS, including weight gain, abdominal
adiposity, elevated fasting blood glucose (FBG) and in-
sulin levels, impaired glucose-stimulated insulin se-
cretion, insulin resistance, and dyslipidemia (32). Our
studies also showed that letrozole treatment did not
alter food intake or energy expenditure, even though
locomotion was decreased (32), suggesting that other
mechanisms contribute to the metabolic dysregulation in
this model. Although letrozole treatment results in es-
trogen levels that are lower than estrogen levels in women
with PCOS, we used this model to study the role of the
gut microbiome in PCOS because it recapitulates both
reproductive and metabolic aspects of PCOS. As in
women with PCOS, 16S rRNA gene sequencing showed
that letrozole treatment was associated with lower gut
microbial richness, a shift in the overall gut microbial
composition, and changes in specific Bacteroidetes and
Firmicutes (27). A recent study examining the effects of
nonantibiotic drugs on the gut microbiome found that
letrozole did not alter growth of ;40 representative gut
bacteria (33), which suggests that differences in the gut
microbial composition found in the PCOS mouse model
are not a direct effect of letrozole.
To begin to address whether the gut microbiome
contributes to the pathophysiology of PCOS andwhether
manipulation of the gut microbiome can be used to treat
PCOS, we used a cohousing paradigm to determine
whether exposure to a healthy gut microbiome protected
against development of PCOSmetabolic and reproductive
phenotypes. Because mice are coprophagic, gut mi-
crobes can be readily transferred from one mouse to
another through the fecal-oral route. In this study,
pubertal female mice were treated with placebo or
letrozole and housed two per cage in three different
housing arrangements. The study groups consisted of
placebo mice housed together (P), letrozole mice housed
together (LET), placebo mice cohoused with letrozole
mice (Pch), and letrozole mice cohoused with placebo
mice (LETch). Overall, cohousing letrozole with placebo
mice resulted in substantial improvement in both PCOS
metabolic and reproductive phenotypes compared with
letrozole mice housed together. Furthermore, 16S rRNA
gene sequence analysis demonstrated that cohousing
letrozole with placebo mice resulted in changes in the
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b-diversity of the gut microbiome and highlighted
bacteria that may be candidates for probiotic therapy.
Our findings support the idea that there may be a causal
link between the gut microbiome and PCOS and that
modulation of the gut microbiome may be a potential
treatment option for PCOS.
Materials and Methods
PCOS mouse model
C57BL/6NHsd female mice from Envigo were housed in a
vivarium under specific pathogen-free conditions with an au-
tomatic 12 hour:12 hour light/dark cycle (light period: 06:00 to
18:00) and ad libitum access to water and food (Teklad S-2335
Mouse Breeder Irradiated Diet, Envigo). To establish the pu-
bertal PCOS model, 4-week-old female mice were implanted
subcutaneously with a placebo or 3-mg letrozole pellet (3 mm
diameter; 50 mg/d; Innovative Research of America) for
5 weeks. The 50 mg/d dose was based on the original letrozole
mouse model study (31). For the cohousing paradigm, mice
were housed two per cage in three different cage arrangements:
two placebo mice, two letrozole mice, or one placebo and one
letrozole mouse. The cohousing experimental design resulted in
four groups of mice (n 5 8 per group): P, LET, Pch, and LETch.
All animal procedures in this study were approved by the
University of California, San Diego Institutional Animal Care
and Use Committee (Protocol Number S14011).
Analysis of reproductive phenotype
Mice were weighed weekly. Estrous cycle stage was de-
termined from the predominant cell type in vaginal epithelial
smears obtained during weeks 4 to 5 of treatment as previously
described (31). At the end of the experiment, ovaries were
dissected, weighed, fixed in 4% paraformaldehyde, paraffin-
embedded, sectioned at 10 mm, and stained with hematoxylin
and eosin (Zyagen). Serum testosterone and LH levels were
measured using a mouse ELISA (34) (range 10 to 800 ng/dL)
and a radioimmunoassay (35, 36) (range 0.04 to 75 ng/mL), by
the University of Virginia Center for Research in Reproduction
Ligand Assay and Analysis Core Facility.
Analysis of metabolic phenotype
After 5 weeks of treatment, mice were fasted for 5 hours and
blood from the tail vein was collected to measure fasting insulin
levels. Blood glucose was measured with a handheld glucometer
(One Touch UltraMini, LifeScan, Inc), and an intraperitoneal
insulin tolerance test was performed. Tail vein blood glucose
was measured just before (time 0) an intraperitoneal injection of
insulin (0.75 U/kg in sterile saline; Humulin R U-100, Eli Lilly)
was given and at 15, 30, 45, 60, 90, and 120 minutes after
injection. At the end of the experiment, the mice were anes-
thetized with isoflurane, blood was collected from the posterior
vena cava, and parametrial fat pads were dissected and
weighed. Serum insulin was measured with a mouse ELISA (37)
by the University of California, Davis Mouse Metabolic Phe-
notyping Center.
Quantitative real-time PCR of ovarian genes
Total RNA was isolated from ovaries with an RNeasy Mini
Plus kit (Qiagen), which also removes genomic DNA. cDNA
was made by reverse transcription of total RNA with an iScript
cDNA synthesis kit (Bio-Rad Laboratories). cDNA products
were detected with SYBR Green Supermix (Bio-Rad Labora-
tories) on a Bio-Rad CFX Connect quantitative real-time PCR
system (Bio-Rad Laboratories) with previously described
primers (31). Data were analyzed by the 2-DDCT method (38) by
normalizing the gene of interest to glyceraldehyde 3-phosphate
dehydrogenase. Data were represented as mean fold change
compared with placebo 6 the SEM.
Statistical analysis of reproductive and
metabolic phenotypes
The statistical package JMP 13 (SAS) was used to analyze
differences between groups by one-way ANOVA followed by
post hoc comparisons with the Tukey-Kramer honestly sig-
nificant difference test or two-way repeated-measures ANOVA
followed by post hoc comparisons of individual time points.
Different letters or an asterisk were used to indicate significant
differences (P , 0.05).
Fecal sample collection, DNA isolation, and 16S rRNA
gene sequencing
Fecal samples were collected from 8mice per group (32 mice
total) before treatment and once per week for 5 weeks. Fecal
samples were frozen immediately after collection and stored
at280°C. Bacterial DNA was extracted from the samples with
the DNeasy PowerSoil Kit (Qiagen) and stored at 280°C. The
V4 hypervariable region of the 16S rRNA gene was PCR
amplified with primers 515F and 806R (39). The reverse
primers contained unique 12-bp Golay barcodes that were
incorporated into the PCR amplicons (39). Amplicon sequence
libraries were prepared at the Scripps Research Institute Next
Generation Sequencing Core Facility, where the libraries were
sequenced on an Illumina MiSeq as previously described (27).
16S rRNA gene sequence analysis
Raw sequences were imported into QIIME 2 (version
2018.4) with the q2-tools-import script, and sequences were
demultiplexed with the q2-demux emp-single script. This
procedure resulted in 7.3 million sequences, with an average
of 36,000 sequences per sample. The 16S rRNA sequences
generated in this study were deposited into the European
Nucleotide Archive (Study Accession Number PRJEB29583).
DADA2 software was used to obtain a set of observed sequence
variants (SVs) (40). Based on the quality scores, the forward
reads were truncated at position 240with the q2-dada2-denoise
script. Taxonomy was assigned with a pretrained naive Bayes
classifier (Greengenes 13_8 99% operational taxonomic units)
and the q2-feature-classifier plugin (41). Out of 192 samples, 5
were removed because of insufficient sequence coverage (one
placebo at week 4, two Pch at week 5, and two LETch at week 5),
resulting in 187 samples. In total, 318 SVs were identified from
186 fecal samples. The resulting SVs were then aligned in
MAFFT (42), and a phylogenetic tree was built in FastTree (43).
Taxonomic distributions of the samples were calculated with
the q2-taxa-barplot script. a- and b-diversity metrics were
computed with the q2-diversity core-metrics script at a rarefied
sampling depth of 1250. The a-diversity metric, Faith phylo-
genetic diversity (PD), was used to measure phylogenetic
biodiversity by calculating the total branch lengths on a phy-
logenetic tree of all members in a community (44). UniFrac
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was used to compare the similarity (b-diversity) between the
microbial communities by calculating the shared PD between
pairs of microbial communities (45, 46).
Statistical analysis of 16S rRNA sequences
Statistical calculations were performed in the R statistical
package (version 3.5.1) with the phyloseq (version 1.26.1) (47)
and vegan package (version 2.5.3). a-Diversity data were tested
for normality via the Shapiro-Wilk test. Variables that were not
normally distributed were ranked. Changes in a-diversity over
time were analyzed via simple linear regression and Pearson rank
correlation on ranked diversity measures. Linear mixed effects
analysis of the relationship between a-diversity and time was
done with the lme4 R package (version 1.1.19). P values were
obtained by likelihood ratio tests of the full model with the effect
in question against the model without the effect in question.
Principal coordinate analysis (PCoA) and canonical analysis of
principal coordinates (CAP) plots (48) were constructed in the
phyloseq R package. PCoA plots were used to represent the
similarity of posttreatment (weeks 1 to 5) fecal microbiome
samples based on multiple variables in the data set, and CAPwas
used to visualize the relationship of the fecal microbiome with
specific parameters. Permutational multivariate analysis of var-
iance (PERMANOVA) used posttreatment weighted UniFrac
distance measures to assess bacterial community compositional
differences and its relationship to cohousing treatment group
(999 permutations “vegan” package). DESeq2 (49) (version
1.14.1) in the microbiomeSeq package (version 0.1, http://www.
github.com/umerijaz/microbiomeSeq) was used to identify bac-
terial genera that were differentially abundant between placebo
and LET mice and between LETch and LET.
Results
Cohousing letrozole mice with placebo mice
resulted in less weight gain and
abdominal adiposity
To investigate whether exposure to a healthy gut
microbiome can protect against the development of a
PCOS metabolic and reproductive phenotype, we per-
formed a cohousing study. Female mice were implanted
with a placebo or letrozole pellet at 4 weeks of age and
housed two mice per cage in three different housing
arrangements. This study design resulted in four groups
of mice (n 5 8 per group): P, LET, Pch, and LETch
(Fig. 1A). As shown in Fig. 1B, weight was measured each
week during the 5 weeks of treatment. Similarly to
previously published studies (27, 32), 2 weeks of letro-
zole treatment resulted in increased weight compared
with placebo treatment that was maintained for the rest
of the study (Fig. 1B). Five weeks of letrozole treatment
also resulted in greater abdominal adiposity compared
with placebo treatment (Fig. 1C). Interestingly, Pch mice
had similar weight gain and abdominal adiposity com-
pared with placebo mice. In contrast, LETch mice gained
less weight and exhibited a trend toward less abdominal
adiposity compared with LET mice (Fig. 1B and 1C).
Notably, the protective effect of cohousing letrozole mice
with placebo mice on weight gain manifested only after
several weeks of treatment.
Cohousing letrozole mice with placebo mice
resulted in reduced FBG and insulin levels and
insulin resistance
As reported in previous studies (27, 31, 32), 5 weeks of
letrozole treatment resulted in increased FBG and insulin
levels and insulin resistance (Fig. 1D–1F). Pch mice had
similar serum glucose and insulin levels and insulin
sensitivity to that of placebo mice, whereas LETch mice
had reduced FBG and insulin levels as well as less insulin
resistance compared with LET mice (Fig. 1D–1F).
Cohousing letrozole mice with placebo mice
resulted in estrous cyclicity
In addition to characterizing the effect of cohousing
on the PCOS metabolic phenotype, we also assessed
the effect on the reproductive axis. As previously
published (27, 31), letrozole treatment resulted in
hallmarks of PCOS, including elevated testosterone
and LH levels and acyclicity in LET mice (Fig. 2A–2C).
Pch mice did not have changes in testosterone, LH,
or estrous cyclicity compared with placebo mice
(Fig. 2A–2C). On the other hand, LETch mice had
decreased testosterone and LH levels compared with
LET mice (Fig. 2A and 2B). In addition, LETch mice
displayed changes in the morphology of vaginal epi-
thelial cells representative of different stages of the
estrous cycle compared with the constant diestrus
exhibited by LET mice (Fig. 2C).
Cohousing letrozole mice with placebo mice
protected ovarian function
Consistent with previous reports (27, 31), the ova-
ries of LET mice lacked corpora lutea and displayed
cystic follicles and hemorrhagic cysts, whereas the
ovaries of Pch mice had a similar morphology to that of
placebo mice (Fig. 3A). Interestingly, the ovaries of
LETch mice lacked cystic follicles and hemorrhagic cysts
and contained corpora lutea (Fig. 3A). As in previous
reports (31), LET mice showed a significant increase in
both ovarian weight and ovarian mRNA expression
levels of follicle-stimulating hormone receptor (Fshr),
cytochrome P450 17A1 (Cyp17), and aromatase (Cyp19 )
compared with placebo mice (Fig. 3B–3E). The ovarian
weight and mRNA expression levels in Pch mice mirrored
those of placebo mice (Fig. 3B–3E). Compared with LET
mice, LETch mice showed a significant decrease in ovarian
weight and mRNA expression levels of Cyp17, whereas
Fshr and Cyp19 mRNA expression levels were compa-
rable to those of LET mice (Fig. 3B–3E).
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Gut microbial richness did not correlate with an
improved PCOS phenotype
The overall composition of the gut microbiome from
samples collected before placebo and letrozole treatment
(time 0) was compared between the four groups. No sig-
nificant difference in a- orb-diversity was observed between
the groups, indicating that the gut microbiomes were similar
before treatment (Fig. 4). Linear regression was used to
examine the relationship between a-diversity of the gut
microbiome (Faith PD) and time.Therewas a strongpositive
relationship between a-diversity and time in placebo mice
(r5 0.23) but not LETmice (r5 0.05) (Fig. 5A and 5B). To
account for the repeated measures in this longitudinal study,
we also used a linear mixed-effect model to examine the
association between microbial diversity and time. This
analysis confirmed that there was a significant effect of time
ona-diversity in placebomice (P5 0.003) but not LETmice
(P 5 0.2) (Fig. 5A and 5B). We then investigated whether
changes in a-diversity correlated with improved metabolic
and reproductive phenotypes in the cohoused mice. In
contrast to placebo mice, we did not observe a significant
effect of time on a-diversity on linear regression or the linear
mixed-effect model in Pch mice (r5 0.009; P5 1) or LETch
mice (r 5 0.08; P 5 0.71) (Fig. 5C and 5D).
Composition of the gut microbiome was altered
by cohousing
In addition to investigating changes in a-diversity, we
used weighted UniFrac distances to compare the similarity
of gut microbial composition (b-diversity) between the
different groups. Although visualization of the UniFrac
distances via PCoA did not result in distinct clustering, a
Figure 1. Cohousing letrozole mice with placebo mice protected against development of the PCOS metabolic phenotype. Design of cohousing
study with pubertal female mice housed two per cage in three different housing arrangements that resulted in four groups of mice (n 5 8 per
group): P, LET, Pch, and LETch (A). Letrozole treatment resulted in metabolic dysfunction compared with placebo including (B–F) increased weight,
abdominal adiposity, FBG, and insulin levels and insulin resistance. (B–F) Compared with LET mice, LETch mice showed a decrease in body
weight, a decrease in abdominal adiposity, a decrease in FBG and insulin levels, and restored insulin sensitivity. Graph error bars represent SEM.
Different letters or an asterisk symbol were used to indicate significant differences in a one-way ANOVA or repeated-measures two-way ANOVA
followed by post hoc comparisons with the Tukey-Kramer honestly significant difference test (P , 0.05).
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PERMANOVA test (ADONIS) detected a significant ef-
fect of cohousing treatment on the microbial community
structure (P 5 0.001) (Fig. 6A). This trend was also ob-
served in unweighted UniFrac (data not shown). CAP was
then used to analyze themicrobial composition in response
to an a priori defined experimental variable (cohousing
treatment). PERMANOVA demonstrated a strong re-
lationship between cohousing treatment and the overall
composition of the gut microbiome (P5 0.001) (Fig. 6B),
suggesting that cohousing resulted in a distinct gut mi-
crobial community in LETch mice compared with LET
mice. To understand when the gut microbiome diverged,
we then compared the fecal samples from the four groups
at each time point (Fig. 6C–6G). We observed a significant
separation of the bacterial communities in the treatment
groups after 2 weeks (ADONIS, P 5 0.004) (Fig. 6D).
Separation of the bacterial communities also occurred in
weeks 3 and 4 but not in week 5, possibly because of
convergence of Pch and LETch with a placebo-like gut
microbiome phenotype.
Differentially abundant genera
are associated with cohoused
letrozole mice
Differential abundance of gut bac-
teria between placebo- and letrozole-
treated mice was determined with
DESeq2. This approach used a nega-
tive binomial regression for modeling
count variables and is commonly used
for overdispersed data, which is typical
of microbiome data (33). DESeq2
identified five bacterial genera that
were of higher relative abundance and
four bacterial genera that were of
lower relative abundance in placebo
compared with LET mice (Fig. 7A).
The gram-positive bacteria included
Coprobacillus, Candidatus Arthromi-
tus, Roseburia, Dorea, Lactobacillus,
and Adlercreutzia, and the gram-
negative bacteria included Akkerman-
sia, Christensenella, and Turicibacter.
DESeq2 also identified three bacterial
genera that had an altered relative
abundance in LETch compared with
LET mice: Coprobacillus, Christense-
nella, and Lactobacillus (Fig. 7B).
Discussion
This study demonstrated that exposure
to a healthy gut microbiome resulted in
protection from developing a meta-
bolic phenotype in a PCOS mouse model. In particular,
cohousing letrozole-treated mice with placebo mice
resulted in LETch mice with body weight, FBG and in-
sulin levels, and insulin resistance similar to those of
placebo mice (Fig. 1). Although our results demonstrated
that cohousing letrozole with placebo mice resulted in
protection from metabolic dysregulation by the end of
the study, future studies will be needed to ascertain how
much time cohousing takes to exert a protective effect on
these metabolic factors. The improved PCOS metabolic
phenotype obtained via cohousing is consistent with
previous cohousing studies with obese mice, in which
exposure to a healthy gut microbiome provided pro-
tection from weight gain to germ-free mice inoculated
with feces from obese donors (22). It is worth noting that
the letrozole-induced metabolic phenotype does not in-
volve changes in diet, food intake, or total energy ex-
penditure (32), suggesting that other mechanisms are
responsible for the development of metabolic dysregu-
lation in PCOS. For instance, because studies have
Figure 2. Letrozole mice cohoused with placebo mice did not become hyperandrogenemic
or acyclic. The cohousing study included four groups of mice (n 5 8 per group): P, LET, Pch,
and LETch. Letrozole treatment resulted in increased (A) testosterone and (B) LH levels
compared with placebo. LETch mice displayed a decrease in (A) testosterone and (B) LH and
(C) a restoration of estrous cyclicity compared LET mice stuck in diestrus. Stages of the
estrous cycle are indicated as diestrus (D), metestrus (M), estrus (E), and proestrus (P). Graphs
illustrating the estrous cycle stages of representative mice from the four groups are shown.
Graph error bars represent SEM. Different letters were used to indicate significant differences
in a one-way ANOVA followed by post hoc comparisons with the Tukey-Kramer honestly
significant difference test (P , 0.05).
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indicated that obesity may be influenced by an increased
capacity of the gut microbiome to harvest energy from
dietary fiber (21), it would be informative to test whether
this occurs in letrozole-treated mice.
In addition to an effect of cohousing on the PCOS
metabolic phenotype, this study reports an effect of
cohousing on a reproductive pheno-
type. Specifically, cohousing letrozole
mice with placebo mice resulted in
LETch mice with normalized testos-
terone and LH levels as well as estrous
cycling and ovarian morphology sim-
ilar to those of placebo mice (Figs. 2
and 3). The presence of estrous cycles
and corpora lutea inmany of the LETch
mice suggests that the mice were able to
ovulate. Future superovulation studies
could be informative in determining
whether exposure to a healthy micro-
biome restores ovulation in letrozole-
treated mice cohoused with placebo
mice. Because ovarian Cyp17 gene
expression is induced by both andro-
gens and insulin (50, 51), it is un-
surprising that Cyp17 levels were
normalized in LETch mice (Fig. 3) that
had reduced circulating levels of tes-
tosterone and insulin. On the other
hand, it is not clear why Fshr mRNA
levels were increased in both LET and
LETch mice. With regard to aromatase
(Cyp19) expression, one possible ex-
planation why Cyp19 mRNA levels
did not resolve in LETch mice, despite
normalization of testosterone levels, is
that LETch mice were still exposed to
letrozole. These results support the
idea that suppression of the aromatase
enzymewith letrozole treatment results
in a compensatory increase in Cyp19
mRNA. This study also indicates that
normalization of Cyp19 mRNA was
not necessary for an improved PCOS
phenotype and suggests that the pro-
tective effect of cohousing did not oc-
cur because of decreased letrozole
activity in LETch mice.
To further characterize the effects
of cohousing on the letrozole-induced
PCOS mouse model, we examined the
effects of cohousing on the gut
microbiome. As published previously
(27), we observed lower a-diversity in
letrozole-treated female mice compared with placebo
mice. These results are consistent with studies that re-
ported lower a-diversity of the gut microbiome in women
with PCOS compared with controls (23–25). However,
because we did not observe higher a-diversity in LETch
mice compared with LET mice (Fig. 5), these results
Figure 3. Cohousing letrozole mice with placebo mice improved the ovarian phenotype. The
cohousing study included four groups of mice (n 5 8 per group): P, LET, Pch, and LETch. (A)
Letrozole treatment resulted in a lack of corpora lutea, cystlike follicles, and hemorrhagic
cysts in the ovaries compared with placebo mice. (A) Unlike LET mice, LETch mice lacked
polycystic ovaries, and their ovaries contained corpora lutea (CL) which is evidence of
ovulation. Scale bars represent 250 mm. (B–E) Letrozole treatment also resulted in increased
ovarian weight and increased mRNA expression of several ovarian genes important in ovarian
follicular development and steroidogenesis. (B) Ovarian weight was lower in LETch mice
compared with LET mice. Fshr and Cyp19 mRNA levels were similar between LET and LETch
mice, whereas Cyp17 was lower in LETch mice compared with LET mice. Graph error bars
represent standard error of the mean. Different letters were used to indicate significant
differences in a one-way ANOVA followed by post hoc comparisons with the Tukey-Kramer
honestly significant difference test (P , 0.05).
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indicate that the physiological differences between LET
and LETch mice are probably not due to changes in
a-diversity per se but may reflect changes in specific gut
microbes. Supporting this idea, we
observed changes in the overall gut
bacterial composition at the same time
(Fig. 6; week 2) that we observed a
protective effect of cohousing on
weight gain in LETch mice (Fig. 1B).
Additional support for this idea comes
from the identification of specific gut
bacteria such as Coprobacillus and
Lactobacillus that had a relative abun-
dance altered by letrozole treatment
and restored by cohousing letrozole
with placebo mice. Interestingly, these
bacteria have been linked with host
metabolism. Coprobacillus was re-
ported to be enriched in healthy sub-
jects compared with obese subjects and
was proposed as a novel probiotic
because of its association with a
healthy gut microbiome (52, 53). Although Lactobacillus
is commonly used as a probiotic, increased abundance of
some Lactobacillus species has been reported in obese
humans (54, 55), suggesting that the
effect of Lactobacillus on metabolism
may be species and strain specific (56).
Our results highlight the need for
bacterial species- and strain-level iden-
tification in future studies focused on
the role of the gut microbiome in
PCOS.
Sex differences in the gutmicrobiome
probably arise after puberty through
the action of sex steroids (57). How-
ever, the mechanisms by which sex
steroids influence the gut microbiome
remain unclear. In the case of PCOS,
previous studies in humans and mouse
models of the disorder (23–25, 27)
suggest that elevated testosterone
levels select for different gutmicrobes via
unknown mechanisms. Future studies
investigating the role of androgen and
estrogen receptors in immune cells,
intestine, liver, or other relevant tissues
will be important in determining
whether steroid receptor signaling
in the host is necessary for steroid-
dependent changes in the gut micro-
biome. Additional studies will also be
needed to determine whether andro-
gens can directly regulate gut bacteria
by acting as substrates for bacterial
enzymes, such as b-glucuronidases,
Figure 5. Cohousing letrozole mice with placebo mice did not restore a-diversity of the gut
microbiome. The cohousing study included four groups of mice: (A) P, (B) LET, (C) Pch, and (D)
LETch (n 5 8 per group with the exception of n 5 7 for P time 4 and n 5 6 for Pch and LETch
time 5). a-Diversity as approximated by Faith PD ranked estimate was graphed over time for the
four groups. Results of linear regression model (LM) and P value are in the box insets, and the
gray shaded area indicates the 95% CI for the line of best fit. P values for the linear mixed
effects model (LME) were obtained by the likelihood ratio test of the full model, with the effect
in question (time) against the model without the effect in question, and are in the box insets.
Figure 4. Gut microbiome was similar in all cohousing treatment groups before treatment. The
cohousing study included four groups of mice: P, LET, Pch, and LETch (n 5 8 per group with the
exception of n 5 7 for P time 4 and n 5 6 for Pch and LETch time 5). No significant differences
in (A) gut microbial richness (a-diversity, Faith PD) or (B) community composition (b-diversity,
weighted UniFrac) were observed among cohousing treatment groups before treatment (week
0; n 5 8 per group). One-way ANOVA was used to compare a-diversity among the groups,
and analysis of similarity (ANOSIM) test was used to compare b-diversity among the groups.
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important for producing carbon and
energy as described for estrogens (58).
Although our results suggest that
bacterial exchange may protect against
the PCOS phenotype, it is possible that
exposure to other fecal microbes (e.g.,
archaea), microbial metabolites, or
even steroids in feces and urine could
play a protective role. Fecal micro-
biome transplant studies will be critical
in ruling out the influence of phero-
mones, behavioral interactions, or urine
in the protective effect of cohousing.
Future reconstitution experiments will
also be important to determine whether
specific bacteria or metabolites are
necessary for a protective effect. If
bacteria prove to be an important
component of the protective effect of
cohousing, it is worth considering how
modulating gut bacterial composition
could improve reproductive function.
Because studies have shown that weight
loss in women with PCOS results in
decreased androgen levels and improved
menstrual cycling and fertility (59), it is
possible that gutmicrobesmay indirectly
regulate the reproductive axis through
effects on metabolism. Alternatively, gut
bacteria may have a direct effect on re-
production by controlling the amount of
steroid hormones excreted or reab-
sorbed into enterohepatic circulation
through deconjugation of steroids
conjugated in the liver (60). Although
there are some similarities in the types
of bacteria that are altered in PCOS and
obesity, it remains unclear whether
microbial dysbiosis and metabolic
dysregulation in these two disorders
result from similar mechanisms. Studies
demonstrating that changes in the
gut microbiome and metabolism
are associated with hyperandrogenism
and that PCOS metabolic dysregula-
tion occurs in a body mass index–
independent manner indicate that some
of the mechanisms driving PCOS met-
abolic disturbances are distinct from
those driving metabolic dysregulation in
obesity (6, 23 –25, 7).
In summary, our study demon-
strated that exposure to a healthy gut
Figure 6. Cohousing letrozole mice with placebo mice influenced the overall composition of the gut
bacterial community over time. The cohousing study included four groups of mice: P, LET, Pch, and LETch
(n 5 8 per group with the exception of n 5 7 for P time 4 and n 5 6 for Pch and LETch time 5). (A)
Unconstrained PCoA of weighted UniFrac distances demonstrated changes in the microbial composition
(b-diversity) among samples collected after treatment. Permutational ANOVA of the weighted UniFrac
distances indicated that cohousing had a strong influence on the gut microbial community (P 5 0.001).
(B) Constrained CAP of weighted UniFrac distances further illustrated the relationship between b-diversity
and posttreatment with a significant effect of constraining the data based on the cohousing treatment
group (P 5 0.001). (C–H) Samples from the different groups were then compared at each time point.
Permutational ANOVA of the weighted UniFrac distances was done for each time point.
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microbiome via a cohousing paradigm resulted in pro-
tection from developing metabolic and reproductive
phenotypes in a letrozole-induced PCOS mouse model.
The physiological phenotypes were associated with
changes in the composition of the gut microbiome,
suggesting that modulation of gut microbes toward a
dysbiotic or healthy state may influence the degree of
pathology. It is notable that cohousing also resulted in
changes in the gut bacterial community of placebo mice
cohoused with letrozole mice compared with placebo
mice housed together. However, because these changes
were not sufficient to alter the metabolic and re-
productive phenotypes of the host, these results suggest
that the healthy gut microbiome was resistant to any
pathological influence from the feces of the letrozole
mice. To elucidate how exposure to a healthy gut
microbiome protected mice from developing PCOS, fu-
ture studies are needed to characterize the effects of
cohousing on the composition and function of the gut
microbiome in the letrozole-induced PCOS mouse model
by using metagenomics and metabolomics. In addition,
studies are needed to investigate the mechanisms by
which changes in the gut microbiome influence meta-
bolism and reproduction. Moreover, because these re-
sults imply that modulating the composition of the gut
microbiome may be a potential treatment option for
women with PCOS, future studies should also investigate
whether supplementation with prebiotics or novel pro-
biotics such as Coprobacillus can protect against the
development and pathology of PCOS.
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Figure 7. Specific bacterial genera were associated with
improvement of the PCOS phenotype during cohousing. The
cohousing study included four groups of mice: P, LET, Pch, and LETch
(n 5 8 per group with the exception of n 5 7 for P time 4 and n 5
6 for Pch and LETch time 5). Results from the DESeq2 differential
abundance analysis were expressed as log2 fold change for (A) the
comparison of P and LET mice and (B) the comparison of LETch and
LET mice. Positive log2 fold changes represent bacterial genera
increased in (A) P mice relative to LET mice or (B) LETch relative to LET
mice, whereas negative changes represent bacterial general increased
in (A) LET relative to P mice or (B) LET relative to LETch mice. *P ,
0.05; **P , 0.01; ***P , 0.001.
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DISSERTATION DISCUSSION AND CONCLUSION 
 
The results from these studies have helped answer fundamental questions concerning 
the role of the gut microbiome in the development and pathology of PCOS. Similar to two 
previous studies, chapter 1 demonstrated that women with PCOS had lower microbial 
richness and a shift in gut microbial composition when compared to healthy women [1-4]. 
Through regression analysis we also showed that, similar to the letrozole-induced PCOS 
mouse model, hyperandrogenism was correlated with changes in the gut microbiome in 
women with PCOS. This is particularly impactful because these findings suggest that 
androgens may be an important factor in shaping the gut microbiome and that changes in the 
gut microbiome may influence the development and pathology of PCOS.  
The clinical manifestations of PCOS often emerge around the early reproductive years 
suggesting that puberty is a critical period for the development and pathology of PCOS [5, 6]. 
Furthermore, women with PCOS who are also hyperandrogenic are likely to display a strong 
metabolic phenotype [7, 8]. The results in chapter 2 showed that letrozole treatment of both 
pubertal and adult female mice resulted in reproductive hallmarks of PCOS [9]. However, 
unlike pubertal mice, letrozole treatment in adult female mice resulted in only a modest PCOS 
metabolic phenotype and no insulin resistance. In addition, letrozole treatment of adult mice 
was associated with a distinct shift in the gut microbial community when compared to 
pubertal mice even though specific bacterial genera that changed were present in both ages. 
These results are important because they suggest that timing of excess androgen exposure 
may be an important component in the development of the PCOS metabolic phenotype and 
associated changes in the gut microbiome. 
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In recent years, several human and rodent studies have reported that the gut 
microbiome of individuals with PCOS differs significantly from healthy individuals and 
suggest that microbial imbalance or “dysbiosis” in the gut may contribute to the pathology of 
PCOS [1-4, 10-12]. Using a PCOS mouse model, we addressed whether the gut microbiome 
contributes to the pathophysiology of PCOS and if manipulation of the gut microbiome can be 
used to treat PCOS. The results in chapter 3 significantly added to the microbiome and PCOS 
field by being the first to report that the reproductive and metabolic phenotype of PCOS 
improved with exposure to heathy gut bacteria [13]. These results suggest that altering the gut 
microbiome via pre-/probiotic therapies or introduction of bioactive molecules may be a 
potential treatment option for women with PCOS. 
While the chapters in this thesis focused on the bacterial part of the gut microbiome, it 
is possible that other members of the microbiome (archaea, virus, fungi) also play a 
significant role in the pathophysiology of PCOS. Throughout the chapters, we emphasized the 
need to move beyond the genera level typically obtained through 16S rRNA gene sequencing 
and into the strain level using shotgun metagenomics. This approach will also yield fruitful 
information regarding other members of the gut microbiome and the genes they carry with 
them.  
Nevertheless, if bacteria are involved in the pathophysiology of PCOS, what are the 
mechanisms involved in this process? In order to better understand their potential 
mechanisms, we must first understand current hypotheses pertaining to PCOS pathology. 
PCOS is one of the most poorly understood medical disorders, possible reasons for this 
include the perceived inadequacy of its naming, its heterogenous nature and the uncertainty 
about its etiology and pathophysiology [14, 15]. What is known is that obesity is a common 
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feature of PCOS and up to 80% of women with PCOS are reported to be overweight or obese 
in the U.S. [16]. Obesity can exacerbate many of the reproductive and metabolic 
abnormalities associated with PCOS. Obesity is associated with increased insulin resistance 
and hyperinsulinemia which are also common findings in PCOS [16, 17]. Insulin resistance 
and hyperinsulinemia contribute to androgen excess in PCOS by stimulating ovarian androgen 
production, decreasing serum sex hormone-binding globulin and modulating luteinizing 
hormone pulsatility [18, 19]. One hypothesis suggests that abdominal adiposity together with 
insulin resistance contribute to ovarian and adrenal hyperandrogenism in women with PCOS 
[20, 21]. However, insulin resistance can occur independent of obesity. Furthermore, PCOS is 
not universal in women presenting with insulin resistance and insulin resistance is not 
universal in PCOS either [15]. Another hypothesis on the pathophysiological mechanisms  
underlying PCOS, and one that most closely resembles what we see in the letrozole-induced 
PCOS mouse model, suggest that a primary resulting in androgen excess is essential for the 
development of this syndrome [22]. This theory suggests that a vicious cycle of androgen 
excess favoring abdominal and visceral adiposity facilitates insulin resistance, which in turn 
further facilitates androgen secretion by the ovaries and adrenal glands in women with PCOS 
[15, 20, 23, 24]. 
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Figure 4-1: Timeline of the emergence of metabolic (hyperinsulinemia – HI; weight gain – 
WG; insulin resistance – IR) and gut microbiome changes (gut microbiome – GM) in a 
hyperandrogenic (HA) letrozole induced polycystic ovary syndrome (PCOS) mouse model 
(A). Hypothesis explaining the emergence of the PCOS phenotype as the result of a vicious 
cycle in which androgen excess favors hyperinsulinemia facilitating weight gain, the weight 
gain in combination with hyperinsulinemia gives rise to insulin resistance and perpetuation of 
hyperandrogenism (B). Two possible mechanisms that the gut microbiome could regulate the 
PCOS phenotype is via modulation of androgen levels or modulation of host metabolism (B). 
Hypothesis explaining how bile acids produced by the host (10) and modified by the gut 
microbiota (20) can act as ligands for the farnesoid X receptor (FXR) and vitamin D receptor 
(VDR) and affect the PCOS metabolic phenotype (C). 
Previous work in our lab has demonstrated that hyperandrogenism (HA) and 
hyperinsulinemia (HI) occurs after 1 week of letrozole treatment, weight gain (WG) and 
changes in the gut microbiome (GM) occur by week 2 and insulin resistance (IR) occurs by 
week 4 [10, 13, 25, 26] (Figure 4-1A). I hypothesize that a vicious cycle of androgen excess 
(HA) favoring hyperinsulinemia (HI) facilitates weight gain (WG), the weight gain in 
combination with the hyperinsulinemia eventually gives rise to insulin resistance (IR) 
perpetuating hyperandrogenism in our PCOS mouse model (Figure 4-1B). In this cycle, there 
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are two possible ways that the gut microbiome could have an effect on the PCOS phenotype: 
1. direct modulation of androgen levels or 2. modulation of the host metabolism (Figure 4-
1B).  
In light of these considerations, I hypothesize that the mechanism by which the gut 
microbiome improves the PCOS phenotype is via modulation of the host metabolism. In fact, 
the first-line treatment option for overweight/obese women with PCOS is diet and lifestyle 
interventions [27, 28]. Weight loss in PCOS women has been shown to ameliorate the clinical 
signs and symptoms of PCOS including hyperandrogenism and insulin resistance [29], 
menstrual dysfunction [30] and oligoovulation [31]. Strategies for managing PCOS symptoms 
also include targeting insulin resistance through the use of an insulin-sensitizer such as 
metformin. Metformin has similar effects to lifestyle interventions in terms of weight loss but 
is superior in its effects on decreasing androgen concentrations [32]. Studies have shown that 
changes in the gut microbiome are associated with metabolic disorders such as obesity, type 2 
diabetes and insulin resistance [32-34]. Moreover, studies have reported that transplantation 
of stool from obese donors into germ free mice results in an obese phenotype, suggesting that 
the gut microbiome may play a causative role in metabolic dysregulation. Interestingly, a 
recent study showed that metformin’s ability to increase insulin sensitivity was through the 
gut microbiome and its metabolic metabolites [34].  
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Figure 4-2: Relative abundance of lithocholic acid in the feces of placebo and letrozole treated 
mice at the end of 5 weeks of treatment.  
 
The gut microbiome not only facilitates harvesting of nutrients and energy from the 
diet but also produces numerous metabolites capable of activating host receptors which can 
regulate several host processes, including metabolic processes. One such class of metabolites 
are produced in the liver from cholesterol initially forming primary bile acids which can then 
be metabolized by gut microbiome specific enzymes (e.g. bile salt hydrolases – BSH) forming 
secondary bile acids. Bile acids facilitate fat digestion and absorption and play an integral role 
in shaping the gut microbiota and host physiology [35]. Based on our preliminary work using 
untargeted metabolomics, we noted that a microbially derived secondary bile acid (lithocholic 
acid) differed significantly between placebo and letrozole mice after 5 weeks of treatment 
(Figure 4-2). Since bile acids have been associated with obesity [36] and insulin resistance 
[37], it is interesting to consider the role that they might play in PCOS.  
Secondary bile acids, such as lithocholic acid, can activate vitamin D receptor (VDR) 
mediating vitamin D signaling [38]. Vitamin D plays important roles in metabolic pathways 
affected by PCOS, including insulin resistance and dyslipidemia [39-41]. Vitamin D 
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concentration has been found to be negatively correlated with the severity of the disorder [42]. 
Studies investigating the effect of vitamin D supplementation on women with PCOS have 
reported improvement of the metabolic and reproductive phenotype; however, these results 
have been mixed and they require further randomized interventional studies on a larger group 
of patients [43-47]. 
Nevertheless, an altered bile acid pool composition has been implicated in the 
pathogenesis of several metabolic diseases [35, 36, 48, 49]. With regards to PCOS, primary 
bile acids have been shown to be positively associated with hyperandrogenism in women with 
PCOS [50]. Primary bile acids can function as signaling molecules by binding to the farnesoid 
X receptor (FXR) [51-53]. FXR plays key roles in bile acid homeostasis and acts as a 
metabolic regulator [54]. Interestingly, primary bile acids have been shown to down regulate 
the conversion of androgens to estrogens by activating FXR, which further inhibited the 
expression and activity of aromatase [55]. This suggest that increased primary bile acids 
might act on the aromatase enzyme already being interfered with by letrozole there by 
exacerbating the hyperandrogenism in the letrozole-induced PCOS mouse model. In essence, 
gut microbes could reduce inhibition of the aromatase by shifting the bile acid pool away 
from primary into secondary bile acids capable of influencing host metabolism leading to an 
improved PCOS phenotype (Figure 4-1C). 
Given the association between excess primary bile acids and hyperandrogenism in 
PCOS, future studies should attempt to orally administer gut microbiota-derived bile salt 
hydrolase (BSH) into our mouse model. This could help rebalance the bile acid pool by 
metabolizing the primary bile acids and forming secondary bile acids. If imbalances in the 
primary and secondary bile acid pool are contributing to the PCOS phenotype, I would expect 
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to see amelioration of the PCOS phenotype in letrozole-treated mice given BSH. Primary bile 
acids are known to directly interact with the FXR receptor; however, it is unclear if the FXR 
is playing a role in PCOS. Future studies could administer letrozole to mice with an intestine-
specific knockout of FXR to determine whether activity of this receptor in the intestine is 
required for the PCOS metabolic phenotype and changes in the gut microbiome. 
In addition to exploring the role of bile acids and FXR in the pathology of PCOS, it is 
also important to determine whether the gut microbiome is necessary and sufficient for the 
development of PCOS. Future experiments using a letrozole-induced PCOS germ free mouse 
model or the introduction of letrozole to pubertal mice given broad-spectrum antibiotics will 
be critical. If the gut microbiome is sufficient for the development of the PCOS phenotype, 
then we would not expect mice with depleted gut microbiomes to develop the PCOS 
phenotypes. However, recapitulation of the PCOS phenotype in germ free mice or mice 
treated with broad-spectrum antibiotics would indicate that the gut microbiome is not 
necessary for PCOS development but could be sufficient to protect from the PCOS 
phenotype. Fecal microbiome transplant of a healthy mouse gut microbiome into the 
letrozole-treated germ free or broad-spectrum antibiotic treated PCOS mouse model and 
treatment with pre/probiotics or metabolites will be critical in determining if modulation of 
the gut microbiome is a viable treatment option for women with PCOS.   
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